

8th Health Informatics in Africa Conference (HELINA 2013) Peer-reviewed and selected under the responsibility of the Scientific Programme Committee

Adequacy and Quality of Immunization Data in a Comprehensive Electronic Health Record System

Aggrey Keny^{a*}, Paul Biondich^{b,c}, Shaun Grannis^{b,c}, Martin C. Were^{b,c}

^aREACH Informatics, Academic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya ^bRegenstrief Institute Inc. ^cIndiana University School of Medicine, Indianapolis, Indiana, USA

Background and Purpose: Timely, simultaneous and combined vaccination is important to protect children from common infectious diseases. In a large health care delivery system in Western Kenya, we examined the adequacy and quality of data within the electronic health record (EHR) to assess the feasibility of developing a clinical decision support system to improve childhood vaccination uptake and coverage.

Methods: The study evaluated vaccination information collected and stored in an EHR between 2006 and 2012 involving 23,270 children. Encounters for 10,299 children lacked immunization information and were excluded.

Results: Documentation of vaccination coverage and timeliness is rendered in Kaplan–Meier time-toevent plots. Vaccination coverage at the end of one year ranges from 60% to 90% for all vaccines assessed individually that are part of the Kenya Expanded Program on Immunization (KEPI). Timely documentation of vaccination is low, with 52.8 weeks (95% CI: 52.1, 53.5) for measles vaccine and 29.2 weeks (95% CI: 28.5, 29.8) for the Bacillus Calmette–Guérin (BCG) vaccine. Complete vaccine observations were recorded in 16% of the encounters. Combination and simultaneous vaccine administration had high congruence and consistency.

Conclusion: A clinical decision support system that generates reminders to clinicians and caretakers of children would optimize vaccination uptake and improve overall immunization coverage. To achieve this, immunization data in the EHR must be timely, complete and consistent. Assessed vaccination timeliness is low, despite high coverage. Vaccine observations are often incomplete. There is need to improve the data collection process to achieve data quality levels that can adequately support a clinical decision support system.

Keywords: Vaccination, Electronic health records, Developing countries, Data quality

1 Introduction

Throughout the world, the use of vaccines has helped to save many lives. The Expanded Program on Immunization, created in 1974, is considered one of the world's most successful public health initiatives of the 20th century [1]. The Global Alliance for Vaccines and Immunization, which supports vaccination programs in developing countries, estimates that by 2010 its work supporting vaccination helped avert approximately 5 million pediatric deaths worldwide [2]. Vaccination programs have proven to be highly cost effective, and are important in achieving Millennium Development Goal 4, which calls for reduction by two-thirds of under-5 mortality by 2015[3]. In developing countries, vaccination programs also form a fundamental part of the healthcare systems. This is because vaccination sessions provide additional opportunities to deliver other health care services that might otherwise be missed, including treatment for malnutrition, malaria, intestinal worms, growth monitoring, breast feeding education, among others [4].

*Corresponding author: REACH Informatics, Academic Model Providing Access to Healthcare (AMPATH), P. O. Box 9157 Eldoret, 30100, Kenya. Email: agris57@yahoo.com, Tel: +254-722-571562

HELINA 2013 M. Korpela et al. (Eds.)

^{© 2013} HELINA and JHIA. This is an Open Access article published online by JHIA and distributed under the terms of the Creative Commons Attribution Non-Commercial License. DOI: 10.12856/JHIA-2013-v1-i1-40

Beyond individual benefits of vaccination, herd immunity can also be achieved when adequate numbers of children are immunized for the particular condition.

In developing countries, immunization information is often collected along with other clinical information as part of routine clinical care for the child. In these cases, the immunization information becomes part of the child's longitudinal record. Well-functioning immunization programs need reliable record systems to assist providers in offering timely and high quality immunization care. These records should include details about a child's prior vaccinations, immunizations administered on a particular visit, and the administration dates for all vaccinations [5]. The same individual immunization data can be aggregated and used by administrators and Ministries of Health in health services planning and to inform healthcare policies. With increasing adoption of Electronic Health Records (EHRs) in developing countries, immunization data is increasingly being stored in an electronic format as part of a longitudinal electronic record [6]. When available electronically, immunization information can potentially be leveraged to deliver automatic reminders and alerts for upcoming or missed immunizations. The immunization information stored can also be aggregated in various ways to best serve the needs of decision-makers at multiple levels.

To best serve the clinical purpose, immunization records need to be part and parcel of the patient's comprehensive record and available to clinicians when needed. As such, cases of isolated immunization databases, often seen as part of some immunization campaigns, rarely reflect the reality of the child's comprehensive clinical record.

EHRs are oftentimes touted as leading to more accurate, timely and readily available data than traditional paper systems [7]. However, almost no research exists to inform on the adequacy with which immunization information collected as part of routine care within EHRs in developing countries actually meet the needs for high quality immunization care [8]. In this study, we critically evaluate the quality and usefulness of child immunization data collected as part of routine clinical visits in a large comprehensive care program in Western Kenya. We particularly focus on how well this data reflects the real picture of immunization services provided, and whether the data passes 'fitness for use' test to inform decisions at individual and systemic levels.

2 Methods

2.1 Study setting

This study was conducted in a large care program formed by the partnership between United States Agency for International Development (USAID) and the Academic Model Providing Access to Healthcare (AMPATH) in Western Kenya [9]. Established in 2001, the AMPATH program is one of the largest comprehensive care programs in sub-Saharan Africa, serving a catchment area of over 2 million individuals through 30 parent and 49 satellite clinical sites. The program offers a broad range of services from antenatal care, pediatric and adult primary care services, HIV care and chronic disease management programs.

At AMPATH clinics, childhood immunizations are offered as per the Kenya Expanded Programme on Immunization (KEPI) schedule, with each child completing routine immunizations in five encounters [10]. The immunizations administered as part of the KEPI schedule are as follows: At Birth - Bacillus Calmette-Guerin (BCG) and Oral Polio (Polio 0); At 6, 10 and 14 weeks of age the children receive Oral Polio, Pentavalent, and Pneumococcal Conjugate vaccines at each of these visits. Measles vaccine is administered last at the age of 9 months. Pentavalent vaccine is a combination vaccine comprised of Diptheria, Pertusis, Tetanus (DPT), Hemophilus influenza Type B (HIB) and Hepatitis B (Hep B) vaccines.

2.2 Immunization Records

Since 2004, AMPATH clinics have used the AMPATH Medical Record System (AMRS) to store comprehensive, longitudinal electronic patient records for all enrolled patients [11]. AMRS is the original implementation of OpenMRS, an open-source electronic health record system deployed widely in the developing world [12]. Clinicians caring for AMPATH patients do not enter data directly into AMRS but rather complete paper encounter forms that contain clinical parameters and categorical observations

previously defined and encoded into the AMRS concept dictionary (see Appendix A for pediatric encounter form). Where necessary, clinicians can write down diagnoses, test results, and other observations as free-text if these are not included in checklists on the encounter form. Clerks with basic computer skills and minimal medical knowledge enter data from the encounter forms into the AMRS. The encounter forms are then placed in the patient's paper clinic chart, which is available to the clinician during patient care.

At AMPATH, immunization information is collected within pediatric encounter forms by clinicians at every visit (Appendix A & **Fig. 1**). Immunization information collected include all previous immunizations (**Fig. 1** – Item 32a), whether the child is on schedule with immunizations or not (**Fig. 1** – Item 32b), and the exact immunizations administered during the visit (**Fig. 1** – Item 51e).

	◎ HIB	Dose#:	01	0 2	03	0	BCG						
Pentavalent	O DPT	Dose#:	0 1	0 2	3	0	Measles	Dose#:	01				
Vaccine	O HEP B	Dose#:	01	0 2	03	0	Polio	Dose#:	0 1	0 2	0	3	D 4
0	Completed	All	O	Unkn	own								
2b. Are immuniz	ations on sch	nedule? O	Yes	© No	O Unkn	own							_
2b. Are immuniz	ations on sch	nedule? 💿	Yes	© No	Unkn	lown							
2b. Are immuniz	ations on sch as Ordered To HIB	oday: 🔲 Nor Dose #: 🔘	Yes ne 1 ©	© No 2 ©	O Unkn	own							
2b. Are immuniz 1e. Immunization Pentavalen	ations on sch s Ordered To HIB HIB	oday: Nor Dose #: O Dose #: O	Yes	 No 2 2 	© Unkn 3 3	own BCG	es Do	se #: @ 1					

Fig. 1. Sections of routine clinical encounter form that capture immunization information for a child

2.3 Study Population

This study involved evaluation of immunization data collected for all children enrolled in the AMPATH program clinics and born between January 2006 and December 2010 as represented on **Fig. 2**.



Fig. 2. Study population

2.4 Data Collection

All immunization information for the cohort of children in the study was collected in the paper encounter forms, and the data entered into the AMRS EHR. We used data in the EHR from January 1, 2006 to 31

^{© 2013} HELINA and JHIA. This is an Open Access article published online by JHIA and distributed under the terms of the Creative Commons Attribution Non-Commercial License. DOI: 10.12856/JHIA-2013-v1-i1-40

March 2012. These dates were chosen because the oldest children in the cohort were born in January 2006, whereas the youngest were born in December 2010. By looking at data until March 2012, we felt comfortable that the youngest children in the study cohort would be expected to have completed the required immunization as per the schedule. For each of the study participants, we extracted demographic information and for each clinical encounter, we extracted historical immunization information, and the vaccine types and value of dose administered.

IRB approval was obtained from the Institutional Research and Ethics Committee at Moi University School of Medicine, Eldoret, Kenya, and Indiana University's Institutional Review Board in Indianapolis, Indiana. All data was de-identified before analysis.

2.5 Outcome measures

The goal of this study was to assess the data quality and adequacy of immunization data collected within the EHR to satisfy the needs of a clinical decision support system aimed at improving immunization in the relevant population. Data quality dimensions that are generally accepted as depicting the real world scenarios are accuracy, timeliness, completeness, precision and consistency [13]-[17]. As pertains to immunization data quality, these dimensions have been refined in the General Recommendation on Immunization [18]. Since these redefined dimensions are better at ascertaining the accuracy and adequacy of immunization data, we chose to apply these in our analysis. These are:

- 1. Timeliness. Age appropriate administration of vaccines as recommended based on demonstrated efficacy and safety for specific age groups at risk of experiencing the disease. Timely vaccinations induce adequate immunity.
- **2.** Spacing of the multiple sources of the same antigen. Optimal immune response is achieved when doses of the same vaccine are administered at recommended intervals.
- **3.** Simultaneous administration. Administering more than one vaccine on the same clinic day, at different anatomic sites, and not combined in the same syringe. There is adequate scientific basis for simultaneously administering all vaccines for which a child is eligible at the time of a visit and this increases the probability of age appropriate compliance.
- **4.** Combination vaccines. Combination vaccines merge equivalent component vaccines into single products to prevent more than one disease or to protect against multiple strains of infectious agents causing the same disease. This also reduces the number of injections patients receive and alleviates concerns associated with the number of injections.

2.6 Data analysis

MYSQL was used to extract the data from AMRS and analysis was done in SPSS version 19. The analyses were confined to 23,270 children aged 15 - 75 months (born between 1 January 2006 and 31 December 2010) excluding 10,299 children due to missing vaccination information. A reference date of 31 March 2012 was set for age calculations and vaccination observations made after this date were excluded.

Age appropriate vaccination uptake (timeliness) was estimated by the Kaplan-Meier method with age in weeks as the timescale [19][20]. Vaccination coverage at age t was estimated by 1 - SKM (t), the Kaplan-Meier survival function; 1 - SKM (t) is the cumulative probability of being vaccinated by age t. Comparison of survival distribution from cohort to cohort was carried out using Log Rank and Tarone-Ware techniques [21].

3 Results

A total of 23,270 eligible children (49.3% male, 50.7% female), aged 15 - 75 months in a total of 272,926 encounters and 1,258,348 immunization observations comprising 5 birth cohorts were included in the study period from 1 January 2006 to 31 March 2012. 10,299 children did not have any immunization data collected during this period. The mean age for the study subjects was 42 months (SD 17.4). The distribution of children in the cohorts is 3,125 in 2006; 3,848 in 2007; 4,095 in 2008; 5,359 in 2009 and 6,843 in 2010 cohorts.

^{© 2013} HELINA and JHIA. This is an Open Access article published online by JHIA and distributed under the terms of the Creative Commons Attribution Non-Commercial License. DOI: 10.12856/JHIA-2013-v1-i1-40

Kaplan-Meier estimates show an overall systematic reduction in the mean time of recording of the first immunization observation over time towards the recommended age of vaccine administration. This trend is best demonstrated by measles observations with a mean time of 38.240 (95% CI: 37.728, 38.751) weeks against the recommended age of 36 weeks in the last cohort (2010), however the overall mean time throughout the 5 cohorts is slightly higher, 52.804 (95% CI: 52.147,53.462). The first vaccine in the schedule, BCG, takes longer to be administered or recorded in the system with a mean overall time of 29.162 (95% CI: 28.482, 29.841) weeks, but this interval reduces over time through the cohorts (**Fig. 3** and **Fig. 4**).

The time course of completion of BCG and DPT series vaccinations is described graphically in **Fig. 3**.It is evident that for both BCG and DPT the series completion of primary vaccination is achieved by only about 10% of the children by the recommended time of 14 weeks at most, and it takes another 300 weeks for all children to have the vaccine observations recorded.



Fig. 3. Age at recording of vaccine observations presented in Kaplan–Meier plots (inverse and cumulative) for BCG and DPT. The X-axis is the age in weeks (used in KEPI schedule) and the Y-axis is the proportion of vaccine observations at each time point. The red vertical lines indicate the recommended age for vaccination. Age of one year is indicated as a scaling (green vertical dotted line), and is the age when all the vaccines are required to have been completed.



Fig. 4. Age at recording of vaccine observations presented in Kaplan–Meier plots (inverse and cumulative) for Oral Polio and Measles

Up to 80% of all children have their observations recorded by their first birthdays, demonstrated by steeper survival curves. After the first year, the curves generally plateau off and it takes much longer for the remaining children to have their vaccine observations administered or recorded. This also explains why most vaccine coverage estimations in the region are found to be about 80%; since age one year is usually taken as the benchmark for a fully immunized child, against a global recommendation of 90% [22]. This commonly used approach is disadvantageous since vaccination coverage can only be determined for the preset age groups and it is not possible to establish the age at which the defined coverage levels are achieved [20]. The multiple dose vaccines such as DPT and Polio reach the 80% mark within the recommended age of 6 weeks for the first doses in both vaccines. The subsequent doses show less steep curves and reach 80 % after longer time intervals.

Test of equality of survival distributions for the different vaccine and different birth cohorts using Log Rank (Mantel-Cox) and Breslow (Generalized Wilcoxon) methods found significant differences between cohort pairs and overall comparisons. This means that the timeliness of vaccine administration and observation changes over the years; with a systematic improvement from 2006 to 2010 as demonstrated by differences in gradients of the graphs.

In the year 2011, the total number of pentavalent component vaccine observations (DPT,Hep B and HIB) were the highest throughout the study period. During this time, this combination vaccine had a concurrence of 97.4% for the 3 vaccine components. This is expected since these vaccines are administered from the same vial. There was no significant difference between the individual vaccine observations (

Fig. 5).



Fig. 5. Relationship of combination vaccine components for immunization observations in 2011.

Based on the recommendation that all age-appropriate doses of vaccines be administered simultaneously to children for whom no specific contraindications exist at the time of the visit, **Fig. 6** depicts the relationship between Polio and DPT observations through the 5 cohorts [18]. The proportions of DPT observations range from 48.1% to 50.0% while Polio observations range from 50.0% to 51.9% through the 5 cohorts. There are no significant differences between these proportions at alpha 0.05 levels as demonstrated by the overlapping 95% CI bars in the first two cohorts. Polio 0, administered at birth for children born in health facilities, estimated at 40% of all deliveries, contributes to the slightly higher polio observations in the last 3 cohorts, since DPT is not administered at this time [23]. In these 3 cohorts, the 95% CI do not overlap and thus the differences are significant.



Fig. 6. DPT/Polio Observations showing simultaneous administration

Fig. 7 shows an output from the EHR. Each vaccine represented is incomplete and it is not possible to know how far the child is in the vaccination schedule. This is a direct consequence of having 2 checkboxes for each vaccine as clinicians often tick one of the two required places. When they tick only the checkbox with the vaccine type, the system will store that vaccine type without the dosage, and when they only tick the checkbox with dosage, the system stores a value without a corresponding vaccine type. This is a very common phenomenon and

Table 1 shows exactly how this applies to other vaccines for the study duration. Most vaccines have doses 1-3 and polio has 0-4.

9.	IMMUNIZAT	IMMUNIZATION HISTORY								
	PREVIOUS IMMUNIZATIONS ADMINISTERED	NUMBER OF DOSES RECEIVED BEFORE ENROLLMENT								
		4.0								
		1.0								
	BACILLE CAMILE-GUERIN VACCINATION									
		3.0								

Fig. 7. Sample output from AMPATH Medical Record System.

	Table 1	. Completeness	of immu	nization	data t	for multi	ple dose	vaccines
--	---------	----------------	---------	----------	--------	-----------	----------	----------

						VACCIN	E TYPE				
			DPT	Нер В	Polio	HIB	Pneumovax	Penta	PCV 10	Missing	Total
Dose	0	Count	N/A	N/A	798	N/A	N/A	N/A	N/A	935	1,794
value		%			0.4%					2.7%	0.2%
	1	Count	5,391	3,593	5,534	3,623	10	1	19	8,318	26,428
		%	2.9%	2.0%	2.9%	2.0%	3.8%	0.5%	9.7%	24.3%	3.5%
	2	Count	5,252	3,445	5,556	3,445	9	4	41	5,407	23,159
		%	2.9%	1.9%	2.9%	1.9%	3.4%	2.1%	20.9%	15.8%	3.0%
	3	Count	13,111	11,087	5,850	11,099	211	171	128	17,060	58,717
		%	7.1%	6.2%	3.1%	6.2%	79.6 %	90.0%	65.3%	49.9%	7.7%
	4	Count	N/A	N/A	8 <i>,</i> 975	N/A	N/A	N/A	N/A	2,495	11,470
		%			4.7%					7.3%	1.5%
	Missing	Count	160,422	159,609	163,630	159,761	35	14	8		643,479
		%	87.1%	89.8%	86.0%	89.8%	13.2%	7.4%	4.1%		84.1%
Total		Count	184,176	177,734	190,343	177,928	265	190	196	34,215	765,047

4 Discussion

A fully immunized child is one who has received all the recommended immunizations within the first one year of life as per the KEPI schedule. This commonly used measure of the proportion of children with specific immunization types at defined ages ('up-to-date') lacks the flexibility of measuring immunization compliance over time and often gives lower compliance figures. EHRs allow visualization of

108

immunization compliance over time. Kaplan-Meier survival plots enable graphic visualization of vaccination at any chosen time interval [20].

Measuring immunization compliance at specific ages recommended for particular vaccine administration and at the age of 1 year showed significantly low rates compared to the overall rates achieved at the end of the study period. This could be explained in two ways; delays in vaccine administration and information system time lag between vaccine administration and recording [24]. Actual delays in vaccine administration are common in the setting where this study was carried out and there are many shortfalls in the healthcare system and personal factors that result in this. Identified characteristics of a well-functioning vaccination systems that promote timely vaccination include availability of health services at all times, short distances and waiting times, media promotion and campaigns [24]. The time intervals between vaccine administration and recording into the EHR vary, and could affect calculation of compliance rates when these intervals are large because vaccine observations are recorded on the date of encounter and not the date of administration.

In the 5 cohorts, there is a general trend of improvement in compliance rates at the age appropriate intervals as time progresses. Whereas the compliance rate of BCG in 2006 is about 60% at the age of one year, it is over 90% in 2010 at the same age. The EHR was relatively new in 2006 and clinicians and other users were still getting used to use it. This phase of learning involves not only getting used to the new encounter forms and workflows, but also disrupts routine tasks and interrupts existing workflows in the healthcare processes with record keeping and data quality falling behind the previous schedules [25]. By 2010, extensive use of the encounter forms and full integration into the workflows resulted in marked improvements in timeliness and therefore, compliance rates. This is important because timely vaccination aside from good coverage, offers better protection from diseases such as Pertussis, Measles and Haemophilus Influenzae type B [26]-[28]. However, we do not know for sure whether the changes in timeliness are due to changes in the recording process or healthcare administrative processes because the system records vaccine observations as per encounter dates and not administration dates. To adequately address this phenomenon, we will carry out another analysis after redesigning the encounter form to take into consideration human and system factors that affect vaccine data quality.

Other studies have found similar differences between up-to date and age-appropriate vaccination [20] [29]. However, in this study care must be taken when evaluating compliance across time because data delay and ongoing processes yield incomplete data and comparison at face value may not be fully valid. In addition, there are logistical challenges such as failure to store sufficient vaccine stocks at all times, poor cold chain system maintenance, and inadequate staffing at health facilities that further reduce compliance rates [30].

Simultaneous and combined vaccine administrations were found to have high consistencies and concurrence among the various affected vaccine observations. This is associated not only with reduced number of injections, but also improves the main target of vaccination programs: timely and complete protection [31].

Findings from this study are mostly consistent with other reports on analysis of EHRs. While EHRs provide a versatile means of information storage and access, there are associated deficiencies in clinical and managerial applications [25]. There are many reasons for this, ranging from people dynamics to electronic tools. In relatively new systems, like the AMRS, the learning process is still taking place. The data collection forms and processes are initially still being refined and the personnel are getting used to the new system. Completeness was found to have the lowest data quality across all data variables (

Table 1). We found that providers often did not complete the immunization fields as required in the forms. They would check the vaccine type and leave out the dose and vice versa. This made it difficult to calculate the spacing between different doses of the same antigen, as this requires vaccine type and dosage values to be present.

Decision support tools are important in promoting structured data entry and other determinants of data quality [16]. Since data entry is a tedious process and consumes a considerable amount of clinicians' and data entry clerks' time, it would be efficient to collect only new and relevant data during every encounter. The design of the encounter forms plays a significant role in data quality. 10,299 (30.1%) of the children had missing immunization observations attributable to the encounter type used in this group. The Rural Health Centre Encounter form does not have the section on 'previous immunizations' and only collects 'ordered' (given today) immunization observations (See appendix 2), which directly contributes to significant missing data.

As a result of this evaluation, the encounter form has been significantly improved to take into consideration human factors that affect data quality and effective data collection processes. The immunization sections on the redesigned encounter forms are depicted on **Fig. 8**. In this design, the separation of vaccines and dosages has been eliminated and these now appear as one combined tickable checkbox for each vaccine given. Combined vaccine Pentavalent is now represented as one vaccine instead of individual components. The arrangement also corresponds to the KEPI schedule and it is convenient for clinicians to check all vaccines in a row that are given at the same time.

10I. Previous Imr	nunizations: 🗆	None 🛛 🗘	Completed Schedule			
🗆 BCG	Polio 0					
Penta 1	Polio 1		PCV 1	Rotavirus 1		□ Vitamin A (children
Penta 2	🗆 Polio 2		PCV 2	□ Rotavirus 2_ (g	iven before 6 months)	under five only)
Penta 3	Polio 3		PCV 3	Measles 0 (6mo)	nths)	s (9months)
10m.Immunizatio	ons confirmed fro	om card 🛛 🗅 Y	es 🗆 No			
40. Immunizations	Ordered Today	None	Completed Schedule)		
🗆 BCG	Polio 0					
Penta 1	Polio 1	PCV 1	Rotavirus 1			
🗆 Penta 2	🗆 Polio 2	PCV 2	□ Rotavirus 2_ (g	iven before 6 months)		en under live only)
Penta 3	Polio 3	PCV 3	Measles 0 (6mo)	nths)	(9months)	

Fig. 8. Immunization section on redesigned AMPATH pediatric encounter form

4.1 Limitations

Generalizability of these findings is limited to settings with similar characteristics. The study uses vaccine observation times rather than administration times.

In some cases, it may be justified to postpone vaccination temporarily when children are moderately or severely ill. Vaccination is then recommended to be given soon after recovery. This was not assessed nor analyzed.

5 Conclusion

Data quality is affected by many factors involving data collection, storage and retrieval. Development of a clinical decision support system that generates reminders directed at clinicians and parents with immunization eligible children would optimize vaccination uptake and improve overall immunization coverage. This study found low age-appropriate vaccination status and high overall vaccination coverage which implies that vaccine administration and recording into the EHR are not timely. Many children were unprotected by vaccination for several months despite being vaccinated at the end of follow-up. The data collection through ticking of checkboxes on paper encounter forms contributes to incomplete data when clinicians fail to tick all the required checkboxes. To achieve data quality levels adequate for a clinical decision support, data collection processes need to be improved through form redesign and clinician sensitization.

References

- Centers for Disease Control and Prevention (US). Ten Great Public Health Achievements--United States, 1900-1999.MMWR Recomm Rep.1999; 48(12): p. 241.
- [2] GAVI. GAVI Alliance Progress Report 2010. 2010.
- [3] UNICEF. A World Fit for Children. Proceedings of the Millennium Development Goals; Special Session on Children Documents; The Convention on the Rights of the Child Conference; 2002 July; New York, US. New York, US: UNICEF;2002
- [4] Wolfson LJ, Gasse F, Lee-Martin SP, Lydon P, Magan A, Tibouti A, Johns B, Hutubessy R, Salama P, Okwo-Bele JM. Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015. B World Health Organ, 2008; 86(1): p. 27-39.
- [5] Stevens LA, Palma JP, Pandher KK, Longhurst CA. Immunization registries in the EMR Era. Online J Public Health Inform, 2013; 5(2): p. 211.

- [6] Williams F,Boren SA. The role of the electronic medical record (EMR) in care delivery development in developing countries: a systematic review. Inform Prim Care, 2008; 16(2): p. 139-145.
- [7] Ndira SP, Rosenberger KD, Wetter T. Assessment of data quality of and staff satisfaction with an electronic health record system in a developing country (Uganda): a qualitative and quantitative comparative study. Methods Inf Med, 2008; 47(6): p. 489-98.
- [8] Weiner JP, Fowles JB, Chan KS. New paradigms for measuring clinical performance using electronic health records. Int J Qual Health Care 2012; 24(3): p. 200-5.
- [9] Einterz RM, Kimaiyo S, Mengech HN, Khwa-Otsyula BO, Esamai F, Quigley F, Mamlin JJ. Responding to the HIV pandemic: the power of an academic medical partnership. Acad Med, 2007; 82(8): p. 812-8.
- [10] Bjerregaard P. [Vaccination of children in Kenya]. Ugeskr Laeger, 1989; 151(48): p. 3221-5.
- [11] Tierney WM, Rotich JK, Hannan TJ, Siika AM, Biondich PG, Mamlin BW, Nyandiko WM, Kimaiyo S, Wools-Kaloustian K, Sidle JE, et al. The AMPATH medical record system: creating, implementing, and sustaining an electronic medical record system to support HIV/AIDS care in western Kenya. Stud Health Technol Inform, 2007; 129(Pt 1): p. 372-6.
- [12] Mamlin BW, Biondich PG, Wolfe BA, Fraser H, Jazayeri D, Allen C, Miranda J, Tierney WM. Cooking up an open source EMR for developing countries: OpenMRS - a recipe for successful collaboration. AMIA Annu Symp Proc, 2006: p. 529-33.
- [13] Batini C, Cappiello C, Francalanci C, Maurino A. Methodologies for data quality assessment and improvement. ACM Comput. Surv., 2009; 41(3): p. 1-52.
- [14] Wand Y,Wang RY. Anchoring data quality dimensions in ontological foundations. Commun. ACM, 1996; 39(11): p. 86-95.
- [15] Wang RY, Strong DM. Beyond accuracy: what data quality means to data consumers. J. Manage. Inf. Syst., 1996; 12(4): p. 5-33.
- [16] Liaw ST, Taggart J, Dennis S, Yeo A. Data quality and fitness for purpose of routinely collected data--a general practice case study from an electronic practice-based research network (ePBRN). AMIA Annu Symp Proc, 2011; 2011: p. 785-94.
- [17] Pipino LL, Lee YW, Wang RY. Data quality assessment. Commun. ACM, 2002; 45(4): p. 211-218.
- [18] Advisory Committee on Immunization Practices (ACIP). General recommendations on immunization.MMWR: Morbidity & Mortality Weekly Report.2011; 60(2): p. 1-64.
- [19] Bland JM, Altman DG. Survival probabilities (the Kaplan-Meier method). BMJ, 1998; 317(7172): p. 1572.
- [20] Laubereau B, Hermann M, Schmitt HJ, Weil J, von Kries R. Detection of delayed vaccinations: a new approach to visualize vaccine uptake. Epidemiol Infect, 2002; 128(2): p. 185-92.
- [21] Wakounig S, Heinze G, Schemper M. Non-parametric estimation of relative risk in survival and associated tests. Stat Methods Med Res, 2011.
- [22] Centers for Disease Control and Prevention (US). Global routine vaccination coverage, 2010.MMWR Recomm Rep.2011; 60: p. 1520-2.
- [23] Izugbara C, Ezeh A, Fotso JC. The persistence and challenges of homebirths: perspectives of traditional birth attendants in urban Kenya. Health Policy Plan, 2009; 24(1): p. 36-45.
- [24] Niederhauser VP, Markowitz M. Barriers to immunizations: Multiethnic parents of under- and unimmunized children speak. J Am Acad Nurse Pract, 2007; 19(1): p. 15-23.
- [25] Gillies A. Assessing and improving the quality of information for health evaluation and promotion. Methods Inf Med, 2000; 39(3): p. 208-12.
- [26] von Kries RBOWA. Haemophilus influenzae b-vaccination: the urgency for timely vaccination. European Journal of Pediatrics, 1997; 156(4): p. 282.
- [27] Grant CC, Roberts M, Scragg R, Stewart J, Lennon D, Kivell D, Ford R, Menzies R. Delayed immunisation and risk of pertussis in infants: unmatched case-control study. BMJ, 2003; 326(7394): p. 852-3.
- [28] The National Vaccine Advisory Committee. The measles epidemic. The problems, barriers, and recommendations. JAMA Pediatr.1991; 266(11): p. 1547-52.
- [29] Dayan GH, Shaw KM, Baughman AL, Orellana LC, Forlenza R, Ellis A, Chaui J, Kaplan S, Strebel P. Assessment of delay in age-appropriate vaccination using survival analysis. Am J Epidemiol, 2006; 163(6): p. 561-70.
- [30] Fadnes LT, Nankabirwa V, Sommerfelt H, Tylleskar T, Tumwine JK, Engebretsen IM. Is vaccination coverage a good indicator of age-appropriate vaccination? A prospective study from Uganda. Vaccine, 2011; 29(19): p. 3564-70.
- [31] Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J, 2006; 25(6): p. 507-12.

Appendix A: AMPATH Pediatric Clinical Encounter Form

COSAID ANIPATH	PAEDIATRIC	RETURN VISIT FOR	Date:
PARTNERSHIP			/ /
1.Name:	AN	IPATHID:	Previous ID:
			Mother's AMPATH ID
2. DOB: 1 1 3. Mother Deceased: OVes ONo OUnk	Age:Trs.	A C Scheduled C Lins	cheduled Early D Unscheduled Late
Father deceased: Ves No Unk	nown	4.11 Concoured 11 Ons	circules carry in onsciedules care
5. Clinic Location:		6. Category:	7. Person Bringing Patient:
MTRH Module: a1 a 2 a 3 a 4 Chulaimbo a 1	o 2 Busia o 1 o 2	D Pilot DMTCT Plus	Mother Father Sibling
Khunyangu o Kitale o Mosoriot o Mt. Elgon o I	Naitiri o Port Victoria o Teso	a Awaiting Assignment	
D UG District Hospital D Webuye D Moi's Bridge	n Moi University no Soy	oResearch oOther:	Unde DP DM
nambale - Mukhobola - Bumala A	A		Children's home Other
8. Current Feeding: tick all that apply	9. Previous	mmunizations: DBCG	
Breast Formula Cow's/Ani	imal milk HIB Dos	e#: 01 02 03 0 Mea	sles Dose#: □1
Expressed Breast milk Other liqu	ids HEP B Dos	e#: 01 02 03 0 Polic	Dose#: 01 02 03 04
Water Solid Foo	d DTP Dos	e#: 01 02 03 0 Con	pleted all Unknown
Yes No Unknown	If yes, are	they registered in Pediatric	HIV clinic? DYes No DUnknown
	If yes AMF	ATH ID's: 1.	2.
12. Child's Current HIV Status: HIV ex	xposed, status indetermin	ate HIV infected	HIV Negative
13. Has patient been hospitalized since	last visit? Ves N	o Reason:	
14. Does Unite have a disability? Ye 15. Current Medications:	Ity Ity	es, specity.	
15a. ARVs: Yes No Is this the patie	nt's Primary Regimen?	Yes No Reason for	ARV's: DoMTCT Clinical disease
3TC (4mg/kg): Syrup mgm	Tabs mg DK	aletra (0.125ml/kg): Syn	ip mgml ⊡Tabs mg
□ d4T (1mg/kg): □ Tabs □15 □ 20 □ 3	30 mg 🗆	ABC (8mg/kg): Syru	p mgml
□ AZT: (180mg/m2): □ Syrupmg_	ml 🗆 Tabs mg	DDI (100mg/m2): Syru	pmgml
GRVP: GSyrupmgmi Gia	bs mg	Neltinavir: D Po	wder mg labs mg
15b. PCP Prophylaxis: None Sept	nn Dapsone	15c TB Prophylaxis	None INH
15d. TB Treatment: None Comp	leted (Date: / /) Rifater Rifinah	(Rifampin/INH)
Rifampicin INH Pyrazinami	ide 🗆 Ethambutol 🛛	Streptomycin Start Da	ate of TB treatment:_/_/
15e.Cryptococcus Tx: None Diflue	can	15f.Other Drugs:	
16 Adherence:			
AC- Whether the state of the set of the set	the set of		
16a. Who has been giving the medicine t	to the patient? (Please t	ick all that apply):	Other (Specify):
16a. Who has been giving the medicine t Mother Father Sibling Grandparer 16b. During the last month has the patier	to the patient? (Please t ntAuntieUncle nt missed any medication	ick all that apply): Self Children's Home	DOther (Specify):
16a. Who has been giving the medicine t Mother □Father □Sibling □Grandparer 16b. During the last month has the patier □ ARVS □ PCP Prophylaxis	to the patient? (Please t Auntie Uncle nt missed any medications TB Prophylaxis	ick all that apply): Self	Dother (Specify):
16a. Who has been giving the medicine t Mother □Father □Sibling □Grandparer 16b. During the last month has the patier □ ARVS □ PCP Prophylaxis Drug(s) Missed:	o the patient? (Please t nt _Auntie _Uncle _ nt missed any medicati TB Prophylaxis Reason:	ick all that apply): SelfChildren's Home ons?YesNo Anti-TB Medication	⊡Other (Specify):
16a. Who has been giving the medicine t Mother □Father □Sibling □Grandparer 16b. During the last month has the patien □ ARVS □ PCP Prophylaxis Drug(s) Missed: 16c. During the last seven days how mar 16c. During the last seven days how mar	o the patient? (Please t nt _Auntie _Uuncle _ nt missed any medication _ TB Prophylaxis 	ick all that apply): SelfChildren's Home ons?YesNo Anti-TB Medication e patient take?	DOther (Specify):
16a. Who has been giving the medicine t Mother □Father □Sibling □Grandparer 16b. During the last month has the patien □ ARVS □ PCP Prophylaxis Drug(s) Missed: 16c. During the last seven days how mar □ ARVS: □ None □ PCP Prophylaxis: □ None	o the patient? (Please t nt @Auntie @Uncle @ nt missed any medication TB Prophylaxis Reason: ny of his/her pills did th Few @ Half @ Few @ Half	ick all that apply): SelfChildren's Home ons?YesNo Anti-TB Medication e patient take? MostAllDrug MostAllDrug	DOther (Specify):
16a. Who has been giving the medicine t Mother □Father □Sibling □Grandparer 16b. During the last month has the patien □ ARVS □ PCP Prophylaxis Drug(s) Missed: 16c. During the last seven days how mar □ ARVS: □ None □ PCP Prophylaxis: □ None □ TB Prophylaxis: □ None	o the patient? (Please t nt _Auntie _Ulnole nt missed any medication TB Prophylaxis Reason: ny of his/her pills did th Pew Half Few Half Few Half	ick all that apply): Self Children's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Most All Drug	DOther (Specify): (s) missed (s) missed (s) missed
16a. Who has been giving the medicine t Mother □Father □Sibling □Grandparer 16b. During the last month has the patier □ ARVS □ PCP Prophylaxis Drug(s) Missed: 16c. During the last seven days how mar □ ARVS: □ None □ PCP Prophylaxis: □ None □ TB Prophylaxis: □ None □ Anti-TB Medication: □ None	o the patient? (Please t ntAuntieUncle nt missed any medication TB Prophylaxis Reason: ny of his/her pills did th E FewHalf E FewHalf E FewHalf FewHalf	ick all that apply): Self Children's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Most All Drug Most All Drug	DOther (Specify): (s) missed (s) missed (s) missed (s) missed (s) missed
16a. Who has been giving the medicine t Mother □Father □Sibling □Grandparer 16b. During the last month has the patier □ ARVS □ PCP Prophylaxis Drug(s) Missed: 16c. During the last seven days how mar □ ARVS: □ None □ PCP Prophylaxis: □ None □ PCP Prophylaxis: □ None □ TB Prophylaxis: □ None □ Anti-TB Medication: □ None	o the patient? (Please t ntAuntieUncle nt missed any medication TB Prophylaxis Reason: ny of his/her pills did th E FewHalf E FewHalf E FewHalf E FewHalf E FewHalf	ick all that apply): Self Children's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Most All Drug Most All Drug	DOther (Specify): (s) missed (s) missed (s) missed (s) missed
16a. Who has been giving the medicine t Mother □Father □Sibling □Grandparer 16b. During the last month has the patier □ ARVS □ PCP Prophylaxis Drug(s) Missed: 16c. During the last seven days how mar □ ARVS: □ None □ PCP Prophylaxis: □ None □ PCP Prophylaxis: □ None □ TB Prophylaxis: □ None □ ART-B Medication: □ None □ Anti-TB Medication: □ None □ Anti-TB Medication: □ None 17. Does the patient have any interval or □	o the patient? (Please t nt insed any medication in TB Prophylaxis Reason: ny of his/her pills did th Prew Half Prew Half	ick all that apply): Self Children's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Most All Drug Most All Drug	Dother (Specify): (s) missed (s) missed (s) missed (s) missed (s) missed
16a. Who has been giving the medicine t Mother Father Sibling Grandparer 16b. During the last month has the patier ARVS PCP Prophylaxis Drug(s) Missed: 16c. During the last seven days how mar ARVS: None PCP Prophylaxis: None TB Prophylaxis: None Anti-TB Medication: None Anti-TB Medication: None T0. Does the patient have any interval or Diarrhea:	o the patient? (Please t nt missed any medication in the Brophylaxis Reason: the Brophylaxis Reason: the Few Half Few Half Few Half Few Half Months continuous	ick all that apply): Self Children's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Most All Drug Most All Drug Most All Drug Most All Drug Most All Drug	Other (Specify): (s) missed (s)
16a. Who has been giving the medicine t Mother Father Sibling Grandparer 16b. During the last month has the patien ARVS PCP Prophylaxis 16c. During the last seven days how mar ARVS: None 2 ARVS: None PCP Prophylaxis: None 2 ARVS: None TB Prophylaxis: None 3 ARVS: None ARVS: None 4 ARVS: None None 5 PCP Prophylaxis: None None 6 Anti-TB Medication: None 7. Does the patient have any interval or Diarrhea: days 9 Diarrhea: days weeks Modeminal pain:	o the patient? (Please t nt insed any medication in the sed any medicatio	ick all that apply): Self Children's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Most All Drug Most All Drug Most All Drug Nost All Drug Cough: days	Other (Specify): (s) missed (s)
Iba. Who has been giving the medicine t Iba. During the last month has the patien ARVS PCP Prophylaxis Drug(s) Missed: 16c. During the last seven days how mar ARVS: None PCP Prophylaxis: None PCP Prophylaxis: None TB Prophylaxis: None Anti-TB Medication: None Anti-TB Medication: None Diarrhea: days weeks Diarrhea: days weeks Difficulty breathing: days weeks	o the patient? (Please t nt insed any medication in the sed any medicatio	ick all that apply): Self Children's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Most All Drug Most All Drug Most All Drug No Vomiting: days i Cough: days Fever: days	Other (Specify): (s) missed (s) months (s) Continuou (s) weeks (s) Weeks (s) Months (s) Continuou (s) Weeks (s) Wee
Iba. Who has been giving the medicine t Iba. Who has been giving the medicine t Iba. Who has been giving the medicine t Iba. During the last month has the patien ARVS PCP Prophylaxis Iba. During the last seven days how mar ARVS: None PCP Prophylaxis: None PCP Prophylaxis: None TB Prophylaxis: None Anti-TB Medication: None Diarrhea: days weeks Abdominal pain: days weeks Difficulty breathing: days weeks	o the patient? (Please t nt missed any medication in the sea any medicati	ick all that apply): Self Children's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Most All Drug Most All Drug Most All Drug No Vomiting: days Cough: days Fever: days Ear discharge: da	Other (Specify): (s) missed (s) months (s) Continuou (s) weeks (s) Months (c) Continuou (s) weeks (c) Months (c) Continuou (c) Months (c) M
Iba. Who has been giving the medicine t Mother Father Sibling Grandparer Ibb. During the last month has the patien ARVS PCP Prophylaxis Ibc. During the last seven days how mar ARVS: None ARVS: None PCP Prophylaxis: None TB Prophylaxis: None Anti-TB Medication: None Anti-TB Medication: None Anti-TB Medication: None Diarrhea: days weeks Ibig Difficulty breathing: days weeks Ibig Sore throat: days weeks Ibig Skin rash: days weeks Ibig	o the patient? (Please t nt missed any medication TB Prophylaxis Reason: Ty of his/her pills did th Few Half Few Half Few Half Few Half Months continuous Months Continuous Months Continuous Months Continuous Months Continuous Months Continuous Months Continuous	ick all that apply): Self Children's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Most All Drug Most All Drug Most All Drug Cough: days Cough: days Fever: days Ear discharge: da Swelling(specify)	Other (Specify): (s) missed (s) months (continuou) (s) weeks (co
Iba. Who has been giving the medicine t Iba. Who has been giving the last month has the patien Iba. Who has been giving the last month has the patien Iba. Who has been giving the last month has the patien Iba. Who has been giving the last seven days how mar Iba. Drug the last Bedication: None Iba. Anti-IB Medication: None Iba. Anti-IB Medication: None Ibarrhea: Ibarrhea: Ibarrhea: Ibarrhea: Ibarrhea: Ibarrhea: <td>o the patient? (Please t nt int issed any medication int missed any medication int missed any medication Reason: int of his/her pills did th int issed any medication int of his/her pills did th issed any medication int of his/her pills did th issed any medication int of his/her pills did th issed any medication issed any medic</td> <td>ick all that apply): Self Children's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Most All Drug Most All Drug Wo Cough: days Cough: days Ear discharge: days Second Second S</td> <td>Other (Specify): (s) missed (s) missed (s) missed (s) missed (s) missed (weeks Months Continuou (weeks Months Continuou (weeks Months Continuou (s) weeks Months Continu</td>	o the patient? (Please t nt int issed any medication int missed any medication int missed any medication Reason: int of his/her pills did th int issed any medication int of his/her pills did th issed any medication int of his/her pills did th issed any medication int of his/her pills did th issed any medication issed any medic	ick all that apply): Self Children's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Most All Drug Most All Drug Wo Cough: days Cough: days Ear discharge: days Second Second S	Other (Specify): (s) missed (s) missed (s) missed (s) missed (s) missed (weeks Months Continuou (weeks Months Continuou (weeks Months Continuou (s) weeks Months Continu
Iba. Who has been giving the medicine t Mother Father Sibling Grandparer 16b. During the last month has the patien ARVS PCP Prophylaxis Drug(s) Missed: Ite. During the last seven days how mar ARVS: None PCP Prophylaxis: None PCP Prophylaxis: None TB Prophylaxis: None Anti-TB Medication: None Anti-TB Medication: None Diarrhea: days weeks Diarrhea: days weeks Difficulty breathing: days weeks Sore throat: days weeks Difficulty breathing: days weeks	o the patient? (Please t nt insed any medication in the sed any medicatio	ick all that apply): Self Children's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Most All Drug Most All Drug Wo Vomiting: days Cough: days Ear discharge: days Self Children (specify) Other (specify)	Other (Specify): (s) missed (s) missed (s) missed (s) missed (weeks Months Continuou (weeks Months Continuou (weeks Months Continuou (s) weeks Months Continuou (s) week
16a. Who has been giving the medicine t Mother Father Sibling Grandparer 16b. During the last month has the patien ARVS PCP Prophylaxis Drug(s) Missed: 16c. During the last seven days how mar ARVS: None PCP Prophylaxis: None PCP Prophylaxis: None TB Prophylaxis: None Anti-TB Medication: None Anti-TB Medication: None Diarrhea: days weeks Diarrhea: days weeks Difficulty breathing: Example Dither (specify)	o the patient? (Please t nt int issed any medication int missed any medication int missed any medication int missed any medication Reason: int of his/her pills did th int is issed any intervention intervention issed and intervention issed and intervention intervention issed and intervention issed and	ick all that apply): Self Children's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Most All Drug Most All Drug Most All Drug Cough: days Cough: days Ear discharge: days Self Cough Specify Other (specify)	Other (Specify): (s) missed (s) missed (s) missed (s) missed (s) missed (weeks Months Continuou (weeks Months Continuou (weeks Months Continuou (s) weeks Months Continu
Iba. Who has been giving the medicine t Iba. Drug(s) Missed: Iba. Drug the last seven days how mar Iba. Drug the last seven days how mar Iba. Drug the last seven days how mar Iba. PCP Prophylaxis: None Iba. PCP Prophylaxis: None Ibarbed to the prophylaxis: None Ibarbed to the patient have any interval of Ibarrhea: Ibays Ibar (specify)	o the patient? (Please t nt in issed any medication in the season: Profile of the season: Profile	ick all that apply): Self Children's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Most All Drug Most All Drug Most All Drug Cough: days Cough: days Ear discharge: days Ear discharge: days Cough: days Coug	Other (Specify): (s) missed (s) months (continuou) (s) weeks (Months (continuou) (s) weeks (months (continuou) (s) weeks (continuou) (s) week
Iba. Who has been giving the medicine t Iba. During the last month has the patien Iba. ARVS PCP Prophylaxis Drug(s) Missed: None Ibc. During the last seven days how mar Ibc. During the last for the last f	o the patient? (Please t ntAuntieUlucle nt missed any medication TB Prophylaxis Reason: Ty of his/her pills did th Few Half Few Half Few Half Few Half Months Continuous Months Continuous	ick all that apply): Self Children's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Most All Drug Most All Drug Most All Drug Cough: days Cough: days Ear discharge: days Ear discharge: days Cough: days Coug	Other (Specify): (s) missed (s) months (continuou) (s) weeks (months (continuou) (s) weeks (mont
16a. Who has been giving the medicine t Mother Father Sibling Grandparer 16b. During the last month has the patien ARVS PCP Prophylaxis Drug(s) Missed: None PCP Prophylaxis: None ARVS: None PCP Prophylaxis: None PCP Prophylaxis: None Anti-TB Medication: None Anti-TB Medication: None Anti-TB Medication: None Diarrhea: days weeks Difficulty breathing: days weeks Sore throat: days weeks Skin rash: days weeks Other (specify)	o the patient? (Please t nt Auntie Ulucle and nt missed any medication Reason: TB Prophylaxis Reason: Te rew Half Few Half Few Half Few Half Months continuous Months Continuous	ick all that apply): Self Children's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Most All Drug Most All Drug Most All Drug Cough: days Cough: days Ear discharge: days Seler discharge: days Seler discharge: days Cough: days Seler discharge: days Cough: d	Other (Specify): (s) missed (s) months (continuou) (s) weeks (months (continuou) (s) weeks (mont
16a. Who has been giving the medicine t Mother Father Sibling Grandparer 16b. During the last month has the patier ARVS PCP Prophylaxis Drug(s) Missed: 16c. During the last seven days how mar ARVS: None PCP Prophylaxis: None PCP Prophylaxis: None PCP Prophylaxis: None Anti-TB Medication: None Anti-TB Medication: None Anti-TB Medication: None Diarrhea: days weeks Image: Some throat: Some thro	o the patient? (Please t nt missed any medication TB Prophylaxis Reason: Ty of his/her pills did the Few Half Few Half Few Half Few Half Few Half Few Half Months Continuous Months Continuous	ick all that apply): SelfChildren's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Cough: days Cough: days Ear discharge: da Swelling(specify) Other (specify) Other (specify Abnormal KE	Other (Specify): (s) missed (s) months (continuou) (s) weeks (months (continuou) (s) weeks (mont
16a. Who has been giving the medicine t Mother Father Sibling Grandparer 16b. During the last month has the patier ARVS PCP Prophylaxis Drug(s) Missed: 16c. During the last seven days how mar ARVS: None PCP Prophylaxis: None PCP Prophylaxis: None PCP Prophylaxis: None ARUS: None PCP Prophylaxis: None ARti-TB Medication: None Anti-TB Medication: None Diarrhea: days weeks Diffculty breathing: days weeks Sore throat: days weeks Skin rash: days weeks Other (specify)	o the patient? (Please t nt missed any medication TB Prophylaxis Reason: Ty of his/her pills did th Few Half Few Half Few Half Months continuous Months Continuous	ick all that apply): SelfChildren's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Other: days Cough: days Cough: days Ear discharge: da Swelling(specify) Other (specify) Other (specify) Abnormal KE	Other (Specify): (s) missed (s)
16a. Who has been giving the medicine t Mother Father Sibling Grandparer 16b. During the last month has the patier ARVS PCP Prophylaxis Drug(s) Missed: 16c. During the last seven days how mar ARVS: None PCP Prophylaxis: None PCP Prophylaxis: None PCP Prophylaxis: None ARti-TB Medication: None Anti-TB Medication: None Anti-TB Medication: None Diarrhea: days Difficulty breathing: days Other (specify)	o the patient? (Please t nt missed any medication TB Prophylaxis Reason: Ty of his/her pills did th Few Half Few Half Few Half Months continuous Months Continuous	ick all that apply): SelfChildren's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Other: days Cough: days Cough: days Ear discharge: da Swelling(specify) Other (specify) Other (specify) Abnormal HE	Other (Specify): (s) missed (s)
16a. Who has been giving the medicine t Mother Father Sibling Grandparer 16b. During the last month has the patier ARVS PCP Prophylaxis Drug(s) Missed: 16c. During the last seven days how mar ARVS: None PCP Prophylaxis: None PCP Prophylaxis: None TB Prophylaxis: None ART-B Medication: None ART-B Medication: None ART-B Medication: None Anti-TB Medication: None Diarrhea: days weeks Diffoulty breathing: days weeks Sore throat: days weeks Skin rash: days weeks Other (specify)	o the patient? (Please t nt missed any medication TB Prophylaxis Reason: TB Prophylaxis Reason: Ty of his/her pills did the Few Half Few Half Few Half Months continuous Months Continuous	ick all that apply): Self Children's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Most All Drug Most All Drug Most All Drug Most All Drug Cough: days Cough: days Ear discharge: days Ear discharge: days Se Swelling(specify) Other (specify) Other (specify) Second Circ: ush Kaposi Rash Abnormal CV	Other (Specify): (s) missed (s)
16a. Who has been giving the medicine t Mother Father Sibling Grandparer 16b. During the last month has the patien ARVS PCP Prophylaxis Drug(s) Missed: 16c. During the last seven days how mar ARVS: None PCP Prophylaxis: None PCP Prophylaxis: None TB Prophylaxis: None ART-B Medication: None Anti-TB Medication: None Diarrhea: days weeks Diarrhea: days weeks Diffculty breathing: days weeks Sore throat: days weeks Skin rash: days weeks Skin rash: Other (specify)	o the patient? (Please t nt missed any medication TB Prophylaxis Reason: TB Prophylaxis Reason: Ty of his/her pills did the Few Half Few Half Months Continuous Months Continuous	ick all that apply): Self Children's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Most All Drug Most All Drug Most All Drug Cough: days Cough: days Ear discharge: days Ear discharge: days Swelling(specify) Other (specify) Other (specify) Abnormal CV	Other (Specify): (s) missed (s) months (continuou (s) weeks (months (continuou (s) weeks (months (continuou (s) weeks (s) weeks (continuou (s) weeks (s) we

Test	Result	1 185	L Date	1631		-	1 1 2 3 2 2	alle
WBC/mm ³				CD4				
Hgb g/dL				CD8				
MCV			3	CD4%				
Platelets/ mm ^a			1	HIV Long Elisa				
ALC/mm*			1	HIV DNA PCR				
SGPT				Viral Load	_		_	
CYP: Code:				Other:	-	In films		1201
CAR: Code:				-Diffuse abninon-miliany	5=Cauty E-	Cardion	negaly 7-OH	aly er abnorma
20. Current Pediatric Staging		-		- second second of the second se	o ound o			and sectoring
CDC Class: ON OA OB	DC	Criteria		1	New Stage	res	No No	
WHO Stage: 0 1 0 2 0 3	04	Criteria			New Stage	Yes	No No	
Not-applicable: D HIV negative	ve 🗆 H	IV Exposed.	status indete	erminate				
Tuberculosis:	57 - 554 De		1000000	21d. If diagnosed, TB	Diagnosis wa	s done	on basis of:	
21a. Household member diagnos	sed with 1	TB? DYe	s 🗆 No	Household contact		Chronic	c cough (> 2	weeks)
21b. Has the patient been diagno	osed with	TB since th	e last visit	FTT/weight loss		Persiste	ent fever	
Yes No				Suggestive CXR		AAFB p	ositive	
21c. Have you diagnosed this ch	ild with T	B today?		□ TST positive *□ Kei	th Jones scor	e	Other (s	pecify):
Yes No Already on an	nti-TB			* Edward Keith scon	e 'D(F	Refer to	the manual)
If yes, tick all that apply:	Rash a A	nemia 🗆 Li	po-dystrophy	Hepatitis Neuro	pathy a IRIS	Ster	ven-Johnson	syndrome
23. Diagnosis: New Diagnosis	(* Tick *	dosis D	summary s	heet Tick "Remove" to	delete to from): n summ	ary sheet)	
Disanosis	New	Ongoing	Recolued	Disaposis	server to non	New	Ongoing	Perch
1	New	Ungoing	Resolved	3		D	Ungoing	Resolv
2	0	0	0	4		0	0	0
24 Plan:				1-4.				
243 ARVS None DStart ARV	Is DConti	inue Regime	Change	Formulation Chappe B	enimen Pe	dose	CStop All	
3TC (4mg/kg): Syrup d4T (1mg/kg): Tabs AZT: (180mg/m2): Syrup NVP: Syrupmg EFV: Syrupmg 24b. PCP Prophylaxis: None	mg m m m	_ml _Tabs 2030 mg gml Tabsmg artCo	Tabs mg C Tabs m ng C ntinue Regin	Kaletra (0.125ml/kg): ABC (8mg/kg): ig DDI (100mg/m2) Nelfinavir: Other: nen Change Reg	Syrup Syrup Syrup Powder	mg mg mg mg mg	mlTai mlTai mlTa Ta	bs m bs m bs m bs m
3TC (4mg/kg): Syrup	mgm ml ml ml sta Sta s/day or	_mlTabs 2030 mg gml iTabsn Tabsn artCo ity (Specify) ml/day	Tabs mg C Tabs m ng C ntinue Regin	Kaletra (0.125ml/kg): ABC (8mg/kg): ig DDI (100mg/m2) Nelfinavir: Other: nen Change Reg Weight Change apsone mg/day	Syrup Syrup Powder imen Re Other	mg mg mg mg -dose	mlTal mlTal mlTa Ta Ta	bs m bs m bs m bs n
3TC (4mg/kg): □ Syrup 44T (1mg/kg): □ Tabs AZT: (180mg/m2): □ Tabs AZT: (180mg/m2): □ Syrup NVP: □ Syrupmg EFV: □ Syrupmg 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: New Drugs: □ Septrintabs 24c. TB Prophylaxis: □ None	mgm ml ml ml ml stat s/day or	ml Tabs 20 30 mg g_ml 1 Tabs_n Tabs_mg art Co ity (Specify)_ ml/day Start INH	Tabs mg Tabs m ng nttinue Regin / D: Co	Aletra (0.125ml/kg): ABC (8mg/kg): DDI (100mg/m2) Nelfinavir: Other: nen Change Reg Weight Change apsone mg/day ntinue INH R	Syrup Syrup Powder men Re Other	mg	miTai miTai miTa Ta Stop 	bs m bs m bs m bs n
3TC (4mg/kg): Syrup 47 (1mg/kg): Tabs AZT: (180mg/m2): Tabs AZT: (180mg/m2): Syrup NVP: Syrup mg EFV: Syrup mg 24b. PCP Prophylaxis: None Reason for stop/change/re-dose: New Drugs: Septrin tab: 24c. TB Prophylaxis: None Reason for stop/change/re-dose:	mg mg ml ml Statistics s/day or Comp	ml ⊡Tabs 20 □ 30 mg gml □ ITabsm Tabsmg art □ Co ity (Specify) ml/day Start INH leted	Tabs mg ng ntinue Regin / D: Co Toxicity	Aletra (0.125ml/kg): ABC (8mg/kg): DDI (100mg/m2) Nelfinavir: Other: Meight Change Reg Weight Change apsonemg/day ntinue INHR (Specify)	Syrup Syrup Powder Other e-dose Acti	mggggggggggggggggggggggggggggggg	miTai miTai Ta Stop 	bs m bs m bs m bs n
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): □ Tabs □ AZT: (180mg/m2): □ Syrup □ NVP: □ Syrup mg □ EFV: □ Syrup mg 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None 24c. TB Prophylaxis: □ None Reason for stop/change/re-dose: None	mg 15 m ml ml State Comp Comp Weig	ml ⊡Tabs 20 ⊡ 30 mg gnl ⊡ Tabsn Tabsng art ⊡ Co ity (Specify) 	Tabs mg Tabs m ng ntinue Regin r D: Co Toxicity Other	Kaletra (0.125ml/kg): ABC (8mg/kg): ig DDI (100mg/m2) Nelfinavir: Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify)	Syrup Syrup Powder Other e-dose g Dose:	mgmgmgmgmgmgmgmgdoseStop we TBNH	mlTal mlTal mlTa Ta Ta 	os m os m bs m bs m
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): : □ Tabs □ AZT: (180mg/m2): □ Syrup mg □ NVP: □ Syrup mg □ EFV: □ Syrup mg 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None 24c. TB Prophylaxis: □ None Reason for stop/change/re-dose: 24d. TB Treatment: □ None	mg ml ml ml State State State Meigl	ml □Tabs 20 □ 30 mg gnl □ ITabsn Tabsn iTabsn it □ Co ity (Specify) ml/day Start INH leted ht Change rt Induction	Tabs mg mg ntinue Regin Co Toxicity Other Change	Kaletra (0.125ml/kg): ABC (8mg/kg): g DDI (100mg/m2) Nelfinavir: 0 0 Other: 0 men Change Reg Weight Change mg/day ntinue INH Rr (Specify) Di D Continuation	Syrup Syrup Powder other e-dose ag Dose: ontinue Regin	mgmgmgmgmgmgmgmgdoseStop ve TBNHhen	mlTal mlTal mlTa 	osm osm bsm bsm
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): : □ Tabs □ AZT: (180mg/m2): □ Syrup mg □ NVP: Syrup mg □ EFV: □ Syrup mg 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None 24c. TB Prophylaxis: □ None Reason for stop/change/re-dose: 24d. TB Treatment: □ None Reason for stop/change/re-dose: 24d. TB Treatment: □ None	mg 15 c ml c ml c State Comp Weig State Comp	m Tabs 20 30 mg g m Tabs m Tabs m r Co ity (Specify) Milday Start INH leted th Change rt Induction	Tabs mg Tabs m ng nntinue Regin Co Toxicity Change Foxicity (Spe	Kaletra (0.125ml/kg): ABC (8mg/kg): g DDI (100mg/m2) Nelfinavir: 0 Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify)	Syrup Syrup Powder other e-dose actinug Dose: ontinue Regin ht Change	mggggggggggggggggggggggggggggggggggg	mlTai mlTai mlTa Ta Ta Tai Tai Tai Tai 	os m os m bs m bs n
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): : Tabs □ AZT: (180mg/m2): □ Syrup □ NVP: Syrup mg_ □ KVP: Syrup mg_ □ EFV: Syrup mg_ 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None Reason for stop/change/re-dose: None 24d. TB Treatment: □ None Reason for stop/change/re-dose: None None Reason for stop/change/re-dose: New Drugs: Rifater	mg 15 : ml ml Sta Comp Weigl Star Comp Star	ml Tabs 20 30 mg 20 30 mg g_ml 0 ITabs_n Tabs_n ml/day Start INH leted ht Change rt Induction bleted 1 Rfinah	Tabs mg Tabs m ng ntinue Regin Con Con Cother Change Foxicity (Spectabs/dc	Kaletra (0.125ml/kg): ABC (8mg/kg): ig DDI (100mg/m2) Nelfinavir: Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify)	Syrup Syrup Powder other Other dose a Acti ug Dose : ontinue Regin ht Change tabs/day	mgmgmgmgmgmgmgdosestop we TBtNHtNHtNHtOthetEtha	mlTal mlTa mlTa Ta Ta 	osm sm bsm bsm Stop mg/day
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): □ Tabs □ AZT: (180mg/m2): □ Syrup □ NVP: □ Syrup mg □ KVP: □ Syrup mg □ EFV: □ Syrup mg □ 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None Reason for stop/change/re-dose: ■ None 24d. TB Treatment: □ None Reason for stop/change/re-dose: None 24d. TB Treatment: □ None Reason for stop/change/re-dose: ■ Streptomycin □ Streptomycin □ Abs	mg 15 : ml ml Sta Comp Weigl Star s/day weigl Comp	ml Tabs 20 30 mg 20 30 mg 2 ml 1 Tabsn Tabsn iTabsn iTabsn iTabsn ity (Specify) ml/day Start INH leted ht Change th Change th Change ml/day Start INH leted ht Change ml/day Start INH leted Start INH leted Start INH leted Start INH leted Start INH leted Start INH leted Start INH leted Start INH Start INH leted Start INH Start	Tabs mg Tabs m ng ntinue Regin D: Co Toxicity Other Change Toxicity (Spe tabs/d: cinmg	Kaletra (0.125ml/kg): ABC (8mg/kg): ig DDI (100mg/m2) Nefinavir: 0 Other: nen Change Reg Weight Change apsone mg/day ntinue INH Ri (Specify) Rifafour Que weight Change ay Rifafour INH mg	Syrup Syrup Powder other e-dose ug Dose: ontinue Regim ht Change tabs/day	mgmgmgmgmgmgmgdose estimates the stop we TB INHtop the stop	mlTal mlTa mlTa Ta Stop DINH 	osm bsm bsm bsm Stop mg/day
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): □ Tabs □ A2T: (180mg/m2): □ Syrup □ NVP: □ Syrup mg □ EFV: □ Syrup mg □ 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None Reason for stop/change/re-dose: 24d. TB Treatment: □ None Reason for stop/change/re-dose: Streptomycin 24d. 24d. TB Treatment: □ None Reason for stop/change/re-dose: 24d. TB Treatment: □ None Reason for stop/change/re-dose: □ Streptomycin □ Streptomycin 24d.	mgm mlml mlml ml ml ml	ml Tabs 20 30 mg 20 30 mg 20 ml 0 1Tabs n 1Tabs n 1Tabs n 1Tabs n 1Tabs n 1 1Tabs n 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Tabs mg Tabs m ng ntinue Regin Coi Coin Toxicity Cother Change Toxicity (Spec tabs/d; cinmg	Aletra (0.125ml/kg): ABC (8mg/kg): DDI (100mg/m2) Nefinavir: Other: nen Change Reg Weight Change apsone mg/day ntinue INH Ri (Specify)Dr to Continuation C C cify) Weig ay Rifafour INH mg	Syrup Syrup Powder other e-dose a Acti rug Dose: ht Change tabs/day	mgmgmgmgmgmgmgmgdoseStop ve TBNH _NH	mlTal mlTa mlTa Ta Ta Ta 	osm bsm bsm Josm Stop mg/day mg
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): □ Tabs □ A2T: (180mg/m2): □ Syrup □ NVP: □ Syrup mg □ EFV: □ Syrup mg □ 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None New Drugs: □ Septrin tabs 24c. TB Prophylaxis: □ None Reason for stop/change/re-dose: None Reason for stop/change/re-dose: Streptomycin 24d. TB Treatment: □ None Reason for stop/change/re-dose: □ Streptomycin 24d. TB Treatment: □ None Reason for stop/change/re-dose: □ Streptomycin 24e. Immunizations Ordered T □ 1 □ Pentavalent □ 1	mg ml c ml c ml c ml c ml c ml c s/day or Weigl Weigl Stat Comp s/day mg s/day mg roday: HIB DPT	ml Tabs 20 30 mg 20 30 mg 20 11 abs n Tabs n Tabs c 11 abs n c art Co c ty (Specify) ml/day Start INH leted th Change rt Induction leted 1 Rifinah Rifampic Dose#: Dose#: 0	Tabs mg Tabs m ng ntinue Regin Coincity Other Change foxicity (Spe tabs/d: cinmg 123	Aletra (0.125ml/kg): ABC (8mg/kg): DDI (100mg/m2) Nefinavir: Other: nen Change Reg Weight Change apsone mg/day ntinue INH Ri (Specify) to Continuation Cd cify) Weig NH_mg BCG Measles	Syrup Syrup Syrup Powder e-dose e-dose a. Acti rug Dose: bit Change tabs/day Dose#1	mggggggggggggggggggggggggggggggggg	mlTal mlTa mlTa Ta Stop DINH Mg/day Re-dose er mbutol 	osm bsm bsm bsm Stop mg
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): □ Tabs □ AZT: (180mg/m2): □ Syrup □ NVP: □ Syrup mg □ EFV: □ Syrup mg □ 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None New Drugs: Septrin tab: 24c. TB Prophylaxis: □ None Reason for stop/change/re-dose: None Reason for stop/change/re-dose: Streptomycin	mgm mm mm mm 	ml Tabs 20 30 mg 9 ml 40 mg 17 abs mg 9 ml 40 mg 17 abs mg 18	mg mg mg minue Regin mg minue Regin mg minue Regin conter conter conter (Spectrum conter (S	Aletra (0.125ml/kg): ABC (8mg/kg): DDI (100mg/m2) Nelfinavir: Other: nen Change Reg Weight Change apsone mg/day ntinue INH Ro (Specify)Di to Continuation Co cify)Di NHmg BCG Measles Polio	Syrup Syrup Syrup Powder e-dose additional additional additionadditionadditicationadditicationadditicationadditationadd	mggggggggggggggggggggg	mlTal mlTa mlTa Ta Stop DINH g/day 	os m os m bs m bs r mg/day mg
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): □ Tabs □ AZT: (180mg/m2): □ Syrup □ NVP: □ Syrup mg □ EFV: □ Syrup mg □ 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None New Drugs: □ Sprin tab: 24c. TB Prophylaxis: □ None Reason for stop/change/re-dose: None Reason for stop/change/re-dose: None Reason for stop/change/re-dose: Streptomycin 24c. TB Treatment: □ None Reason for stop/change/re-dose: Streptomycin 24c. Immunizations Ordered T □ Streptomycin 24c. Immunizations Ordered T □ H Pentavalent □ H 24f. Feeding plan: □ Breast	mgm mm mm m 	ml Tabs 20 30 mg 20 30 mg 20 30 mg 20 ml 1 Tabs mg art Co ty (Specify) ml/day Start INH leted 1 t Change rt Induction leted 1 Rifinah Rifinah Rifinah Dose#: Dose#: Dose#: Expressed	mg mg mg minue Regin mg minue Regin continue Regin continue Regin conter_ conter_ contery (Spectrum) contery (Spectrum)	Kaletra (0.125ml/kg): ABC (8mg/kg): ig DDI (100mg/m2) Nelfinavir: Other: nen Change Reg Weight Change apsone mg/day ntinue INH Ro (Specify)	Syrup Syrup Syrup Powder Powder other e-dose additional additional addit	mggggggggggggggggggggggggggggggggg	mlTai mlTai mlTa 	osm bsm bsm bsm Stop mg/day mg
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): □ Tabs □ AZT: (180mg/m2): □ Syrup □ NVP: □ Syrup mg □ EFV: □ Syrup mg □ 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None New Drugs: Septrin tabs 24c. TB Prophylaxis: □ None Reason for stop/change/re-dose: None 24d. TB Treatment: □ None Reason for stop/change/re-dose: Streptomycin 24d. TB Treatment: □ None Reason for stop/change/re-dose: □ Streptomycin 24e. Immunizations Ordeced T □ H Pentavalent □ H 24f. Feeding plan: □ Breast □Other liou □	mgm mm mm m 	ml Tabs 20 30 mg 20 30 mg 20 ml 1 1Tabs mg at Co ty (Specify) ml/day Start INH leted th Change rt Induction leted 1 Rifinah Rifampia Dose#: Dose#: Dose#: Dose#: Expressed a, soup, juic	mg Tabsm mg ntinue Regin O: - O: - O: - Toxicity - Other - Change Toxicity (Spe tabs/d: cinmg 1 - 2 - 3 1	Aletra (0.125ml/kg): ABC (8mg/kg): B DDI (100mg/m2) Nelfinavir: Other: Meight Change Reg Weight Change apsone mg/day ntinue INH R (Specify) Di to Continuation C C cify) Rifafour B Rfafour B BCG Measles Polio	Syrup Syrup Syrup Powder other e-dose acting Dose: ontinue Regin ht Change tabs/day Dose#:1 Dose#:1 Con ugali, potatoe	mg	mlTal mlTa mlTa Ta Ta Ta Ta Ta Ta Ta Ta Ta 	osm bsm bsm bsm g/daymg
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): □ Tabs □ AZT: (180mg/m2): □ Syrup □ NVP: □ Syrup mg □ EFV: □ Syrup mg □ 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None 24d. TB Treatment: □ None Reason for stop/change/re-dose: □ Steptomycin 24e. Immunizations Ordered T □ Hentavalent □ Pentavalent □ Hentavalent □ 24f. Feeding plan: □ Breast □ Other liqui If this is a change, reason for cha	mgm mimimi mimi mg	ml Tabs 20 30 mg 20 30 mg g_ml 1 Tabsn Tabsn Tabsn tabsn (Start INH leted t Induction bleted 1 Rifinah_ Rifianpic None Dose#: Dose#: Dose#: Carpensee Affor	Tabs mg Tabs m ng nntinue Regin Co Toxicity Other Change Toxicity (Spec tabs/d: cinmg 1 2 3 1 2 3	Aletra (0.125ml/kg): ABC (8mg/kg): g DDI (100mg/m2) Netfinavir: 0 Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify) 0 to Continuation CC cify) Rifafour 8 Rifafour 9 Rifafour 9 BCG Measles 0 Polio C Formula 0 Solid food (1 Intolerance Othe	Syrup Syrup Syrup Powder imen Re Other e-dose Acting to Dose: 0 to Dose: 1 Dose#: 1 Dose#: 1 Con Con ugali, potatoe r(Specify):	mg	mlTal mlTa mlTa Ta Ta Ta Ta o INH o INH o INH o INH o INH 	os m bs m bs m bs r
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): □ Tabs □ A2T: (180mg/m2): □ Syrup □ KPF: □ Syrup □ EFV: □ Syrup □ EFV: □ Syrup □ 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None Reason for stop/change/re-dose: ■ None 24c. TB Prophylaxis: □ None Reason for stop/change/re-dose: ■ None 24d. TB Treatment: □ None Reason for stop/change/re-dose: ■ Streptomycin 24e. Immunizations Ordered T ■ Pentavalent □ Pentavalent ■ D □ Other Inguil ■ Other Inguil If this is a change, reason for chag ■ Other Inguil If this is a change, reason for chag ■ Other Inguil If this is a change, reason for chag ■ Other Inguil If this is a change, reason for chag ■ Other Inguil If this is a change, reason for chag ■ Other Inguil If this is a change, reason for chag ■ Other Inguil If this is a change, reason for chag ■ Other Inguil If this is a change, reason for chag ■ Other	m mimimimi mimi mi 	ml Tabs 20 30 mg 20 30 mg 20 ml 30 mg 20 ml 30 mg 20 ml 30 mg 30 ml 30 mg 30 ml 30 ml 30 ml 40 ml 30 m	Tabs mg Tabs m ng ntinue Regin Co Co Co Toxicity (Spe- tabs/d: cinmg 123 133	Aletra (0.125ml/kg): ABC (8mg/kg): DDI (100mg/m2) Nelfinavir: Other: Weight Change apsone Weight Change apsone (Specify) to Continuation CC cify) Weig ay Rifafour NHmg BCG Measles Polio C Formula Solid food (Intolerance	Syrup Syrup Syrup Powder Other Other a Acting the Change the Chan	mg	mlTal mlTa mlTa Ta Ta Ta 	osm bsm bsm bsm mg/day mg
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): □ Tabs □ 44T (1mg/kg): □ Tabs □ AZT: (180mg/m2): □ Syrup □ NVP: □ Syrup mg □ EFV: □ Syrup mg □ 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None Reason for stop/change/re-dose: None Reason for stop/change/re-dose: ■ Streptomycin 24d. TB Treatment: □ None Reason for stop/change/re-dose: ■ Streptomycin 24e. Immunizations Ordered T □ 1 □ Pentavalent □ 1 □ Pentavalent □ 1 □ 4f. Feeding plan: □ Breast □ Other Drugs Started or R Drug	mgm mm mm m 	ml Tabs 20 30 mg 20 30 mg g ml 0 ITabsn Tabsn ITabsn iTabsn iTabsn iTabsn content (Specify) ml/day Start INH leted ht Change t Induction oleted Rifampic Dose#: Dos	Tabs mg Tabs m ng ntinue Regin Co Co Toxicity (Spe tabs/d: cinmg 123 123 123 123 123 Breast milk se Se	Aletra (0.125ml/kg): ABC (8mg/kg): g DDI (100mg/m2) Nelfinavir: Other: nen Change Reg Weight Change apsone mg/day ntinue INH Ri (Specify) to Continuation Ci cify) Weight NH_ mg BCG Measles Polio Solid food (Intolerance Othe Freg & Duration	Syrup Syrup Syrup Powder Other e-dose g Dose: ontinue Regin ht Change tabs/day Dose#:1 Dose#:1 Cou ugali, potatoe r(Specify):	mg	mlTal mlTal mlTa Ta 	Stop
 3TC (4mg/kg): Syrup 4TT (1mg/kg): Tabs AZT: (180mg/m2): Syrup NVP: Syrup mg EFV: Syrup mg 24b. PCP Prophylaxis: None Reason for stop/change/re-dose: New Drugs: Septrin tab: 24c. TB Treatment: None Reason for stop/change/re-dose: 24d. TB Treatment: Breast Other Drugs Started or R Drug 1. 	mgm mm mm m 	ml Tabs 20 30 mg 20 30 mg g ml 0 Tabs n Tabs m iTabs control it (Specify) ml/day Start INH leted ht Change th Change th Change Rifampic Dose#:	Tabs mg Tabs m ng ntinue Regin Co Co Toxicity Cother Co Change Toxicity (Spectro tabs/d: cinmg 123 13	Aletra (0.125ml/kg): ABC (8mg/kg): I DDI (100mg/m2) Nelfinavir: Other: nen Change Reg Weight Change apsone mg/day ntinue INH Ri (Specify)Di to Continuation C cify) Weig ay Rifafour INH mg BCG Measles Polio C Formula Solid food (Intolerance Othe Freq & Duration	Syrup Syrup Syrup Powder other e-dose a Acti ug Dose: ht Change th Change tabs/day Dose#:1 Dose#:1 Cougali, potatoe r(Specify):	mg	mlTal mlTal mlTa Ta 	osm bsm losm mg/day mg
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): □ Tabs □ 44T (1mg/kg): □ Tabs □ AZT: (180mg/m2): □ Syrup □ NVP: □ Syrup mg □ EFV: □ Syrup mg □ 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None 24c. TB Prophylaxis: □ None Reason for stop/change/re-dose: □ Streptomycin 24d. TB Treatment: □ None Reason for stop/change/re-dose: □ Streptomycin 24d. TB Treatment: □ None Reason for stop/change/re-dose: □ Streptomycin 24e. Immunizations Ordered T □ H □ Pentavalent □ H □ Pentavalent □ H □ Attribute □ Other Inquint 24f. Feeding plan: Breast □ Other Drugs Started or R □ Drug 1. 2. □	mgm mm mm m 	ml Tabs 20 30 mg 20 30 mg g	a mg	Aletra (0.125ml/kg): ABC (8mg/kg): g DDI (100mg/m2) Nelfinavir: 0 Other: Weight Change Reg Weight Change apsone mg/day ntinue INH R (Specify)Di to Continuation CC cify)Weig ay RifafourDi to Continuation CC cify)Weig ay Rifafour BCG Measles Polio C Formula Solid food (Intolerance Othe Freq & Duration	Syrup Syrup Syrup Powder Other e-dose additional construction ontinue Regin ht Change tobse#: 1 Dose#: 1 Dose#: 1 Conugali, potatoe r(Specify):	mgmgmgmgmgmgmgmgmgdosestop Bstop B	mlTai mlTai mlTai mlTai Tai Tai mlTai Tai Tai Tai 	osm bsm bsm bsm Stop mg mg mg mg
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): □ Tabs □ 44T (1mg/kg): □ Tabs □ AZT: (180mg/m2): □ Syrup □ NVP: □ Syrup mg □ EFV: □ Syrup mg □ 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None New Drugs: Septrin tab: 24c. TB Prophylaxis: □ None Reason for stop/change/re-dose: None Reason for stop/change/re-dose: None Reason for stop/change/re-dose: □ Streptomycin 24e. IB Treatment: □ None Reason for stop/change/re-dose: □ Streptomycin 24e. Immunizations Ordered T □ H Pentavalent □ H Vaccine □ 24f. Feeding plan: □ Breast □Other Inqui □ It this is a change, reason for cha 24g. Other Drugs Started or R Drug 1. 2. 3. □ □	mgm mm mm m 	ml Tabs 20 30 mg 20 30 mg 20 ml 0 1Tabsn Tabsn ml/day Start INH leted ht Change rt Induction leted in 1 Rifinah_ Rifinah_ Dose#: D	Tabs mg Tabs m ng ntinue Regin Con 	Aletra (0.125ml/kg): ABC (8mg/kg): DDI (100mg/m2) Nelfinavir: Other: en Change Reg Weight Change apsone mg/day ntinue INH R (Specify) Di to Continuation Cri cify) Rifafour BCG Measles Polio Formula Solid food (Intolerance Othe	Syrup Syrup Syrup Powder Other e-dose actinug Dose: ontinue Regin ht Change tabs/day Dose#:1 Dose#:1 Dose#:1 Con ugali, potatoe r(Specify):	mgmgmgmgmgmgmgmgmgmgms stopp we to stop we to s	mlTal mlTal mlTa mlTa Ta Ta mlTa Ta Ta Ta Ta 	osm bsm bsm bsm mg/day mg mg
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): □ Tabs □ 44T (1mg/kg): □ Tabs □ AZT: (180mg/m2): □ Syrup □ NVP: □ Syrup mg □ EFV: □ Syrup mg □ 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None New Drugs: Septrin tab: 24c. TB Prophylaxis: □ None Reason for stop/change/re-dose: None Reason for stop/change/re-dose: ■ Streptomycin 24d. TB Treatment: □ None Reason for stop/change/re-dose: □ Streptomycin 24d. TB Treatment: □ None Reason for stop/change/re-dose: □ Streptomycin 24t. Immunizations Ordered T □ H □ Pentavalent □ I □ 24f. Feeding plan: □ Breast □ Other Drugs Started or R Drug 1. 2. 3. 3. 25. Tests Ordered: □	mgm mm mm m 	ml Tabs 20 30 mg 20 30 mg g ml 1 Tabs mg at Co ity (Specify) ml/day Start INH leted ht Change rt Induction bleted 1 Rifinah_ Rifiampic Dose#:	Tabs mg Tabs m ng ntinue Regin Coi Coin Coi Coin Coin Coxicity (Spectrum) Change Toxicity (Spectrum) Change Spectrum) Change Cha	Aletra (0.125ml/kg): ABC (8mg/kg): g DDI (100mg/m2) Nelfinavir: 0 Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify) 0 to Continuation CC cify) Rifafour ay Rifafour BCG Measles Polio Conterance Othe Freq & Duration	Syrup Syrup Syrup Powder Other e-dose actinug Dose: ontinue Regin ht Change tabs/day Dose#:1 Dose#:1 Corugali, potatoe r(Specify):	mgmgmgmgmgmgmgmgmgmgmgms stopp stop	mlTai mlTai mlTa mlTa Tai Tai 	osm bsm bsm bsm mg/day mg mg
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): □ Tabs □ AZT: (180mg/m2): □ Syrup □ REFV: □ Syrup mg □ 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None New Drugs: □ Sprup mg 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None Reason for stop/change/re-dose: None Reason for stop/change/re-dose: ■ Streptomyoin 24c. TB Treatment: □ None Reason for stop/change/re-dose: □ Streptomyoin 24c. Immunizations Ordered T □ Hentavalent □ 24e. Immunizations Ordered T □ Hentavalent □ 24f. Feeding plan: □ Breast □ Other Drugs Started or R Drug 1. □ 2. 3. 25. Tests Ordered: □ Hab	mgm mm mm m 	ml Tabs 20 30 mg 20 30 mg g ml 1 Tabs mg ml/day Start INH leted th Change rt Induction bleted 1 Rifinah_ Rifiampic None Dose#: D	Tabs mg Tabs m ng ntinue Regin r Co 	Aletra (0.125ml/kg): ABC (8mg/kg): DDI (100mg/m2) Netfinavir: Other: Weight Change apsonemg/day ntinue INHR (Specify)D to ContinuationC cify) Weight ContinuationC cify) Weight ayRifafour BCGMeasles Polio C Formula Solid food (Intolerance Other Freq & Duration	Syrup Syrup Syrup Powder imen Re Other e-dose Acting ug Dose: 0 thill Change 1 the Change	mgmgmgmgmgmgmgmgmgstop stop stop stop stop stop stop stop	mlTal mlTal mlTa Ta Ta Ta Ta 	osm bsm bsm bsm mg/day mg
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): □ Tabs □ 44T (1mg/kg): □ Tabs □ AZT: (180mg/m2): □ Syrup □ NVP: □ Syrup mg □ EFV: □ Syrup mg □ 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None Reason for stop/change/re-dose: ■ 24d. TB Treatment: □ None Reason for stop/change/re-dose: ■ 24d. TB Treatment: □ None Reason for stop/change/re-dose: ■ □ Streptomycin	mgm mm mm m Sta Sta Sta Sta Sta Sta 	ml Tabs 20 30 mg 20 30 mg g_ml 0 ITabsn Tabsn Tabsn Ml/day Start INH leted th Change th Changet th C	Tabs mg Tabs m ng ntinue Regin Co Co Toxicity (Spectrosov Toxicity (Spectrosov Toxici	Aletra (0.125ml/kg): ABC (8mg/kg): g DDI (100mg/m2) Nelfinavir: Other: enen Change Reg apsone mg/day ntinue INH R (Specify) to Continuation C C cify) Weight to Continuation C C cify) Weight BCG Measles Polio BCG Measles Polio Freq & Duration Freq & Duration Ctot Panel CXR	Syrup Syrup Syrup Powder e-dose e-dose ontinue Regin (ht Change tabs/day Dose#: Dose#: Dose#: t Cange Cougali, potatoe r(Specify): Viral Load Other (Spec	mg	mlTal mlTal mlTa Ta Ta 	osmg bsm bsm bsm mg/day mg
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): □ Tabs □ 44T (1mg/kg): □ Tabs □ AZT: (180mg/m2): □ Syrup □ NVP: □ Syrup mg □ EFV: □ Syrup mg □ 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None New Drugs: □ Septrin tabs 24d. TB Treatment: □ None Reason for stop/change/re-dose: None Reason for stop/change/re-dose: □ Streptomycin 244. IB Treatment: □ None Reason for stop/change/re-dose: □ Streptomycin 244. Immunizations Ordered T □ 1 Pentavalent □ 1 Pentavalent □ 1 Pentavalent □ 1 Pentavalent □ 1 Quecine □ 1 245. Feeding plan: □ Breast □ Other Drugs Started or R □ Drug □ □ 1. □ □ 25. Tests Ordered: □ □ Full Haemogram □ Hgb HIV Elisa	mgm mm mm m ssta 	ml Tabs 20 30 mg 20 30 mg g ml 0 ITabsn Tabsn Tabsn iTabsn iTabsn iTabsn iTabsn it (Specify) ml/day Start INH leted ht Change t Induction oleted1 Rifinah_ Rifampic Dose#:	Tabs mg Tabs m ng ntinue Regin Co Co Toxicity (Spe tabs/d: cinmg 123 1333 1333 133 1 _	Aletra (0.125ml/kg): ABC (8mg/kg): g DDI (100mg/m2) Nelfinavir: Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify) to Continuation Ci cify) Weight NHmg BCG Measles Polio BCG Solid food (Intolerance Othe Freq & Duration CD4 Panel CXR C	Syrup Syrup Syrup Powder e-dose ug Dose: ontinue Regin ht Change tabs/day Dose#: Dose#: Dose#: to cougali, potatoe r(Specify): Viral Load Other (Spec	mg	mlTal mlTal mlTa Ta 	osmg bsm losm mg/day mg
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): □ Tabs □ 44T (1mg/kg): □ Tabs □ AZT: (180mg/m2): □ Syrup □ NVP: □ Syrup mg □ EFV: □ Syrup mg □ 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None New Drugs: □ Sprin tabs 24c. TB Treatment: □ None Reason for stop/change/re-dose: □ Streptomycin 24c. TB Treatment: □ None Reason for stop/change/re-dose: □ Streptomycin 24c. Immunizations Ordered T □ Hentavalent □ Pentavalent □ Hentavalent □ Pentavalent □ Hentavalent □ Addition Stop/change/re-dose: □ Other Drugs Started or R □ Drug □ 1. □ 24g. Other Drugs Started or R □ Drug □ 1. □ 25. Tests Ordered: □ HiV D □ Full Haemogram □ Hgb □ HIV Elisa □ HIV D 26. Referrals: □ None	mgm mm mm m 	ml Tabs 20 30 mg 20 30 mg gnl 0 iTabsn Tabsn iTabsn ml/day Start INH leted1 Rifinah Rifinah Rifinah Rifinah Rifinah Rifinah Rifinah Rifinah Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Creat gramA	Tabs mg Tabs m ng ntinue Regin Co Co Toxicity Cother Co Toxicity (Spectrosovic) Change Toxicity (Spectros	Aletra (0.125ml/kg): ABC (8mg/kg): g DDI (100mg/m2) Nefinavir: Other: nen Change Reg Weight Change apsone mg/day ntinue INH Ri (Specify)Di to Continuation C to Continuation C to Continuation C cify)Neg BCG Measles Polio BCG Measles Polio Solid food (Intolerance Othe Freq & Duration CCD4 Panel CXR C	Syrup Syrup Syrup Powder e-dose ug Dose: Action the Regin th Change th Change th Change th Change to pose#: Dose#: ugali, potatoe r(Specify): Viral Load Other (Specify):	mggg	mlTai Tai Tai	osm bsm bsm bsm bsm mg/day mg mg mg mg mg
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): □ Tabs □ 44T (1mg/kg): □ Tabs □ AZT: (180mg/m2): □ Syrup □ NVP: □ Syrup mg □ EFV: □ Syrup mg □ 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None New Drugs: Septin tab: 24c. TB Prophylaxis: □ None Reason for stop/change/re-dose: None Reason for stop/change/re-dose: None Reason for stop/change/re-dose: □ Streptomycin 24c. TB Treatment: □ None Reason for stop/change/re-dose: □ Streptomycin 24e. Immunizations Ordered T □ H Pentavalent □ H □ Pentavalent □ H □ Attriang □ Other liqui If this is a change, reason for cha 24g. Other Drugs Started or R Drug 1. □ 1. □ □ 2. □ □ 3. 25. Tests Ordered: □ HIV D 26. Referrals: □ None □ TB treatment!	mgm mm mm m	ml Tabs 20 30 mg 20 30 mg g ml 31 Tabs mg art Co ty (Specify) ml/day Start INH leted ht Change rt Induction leted in 1 Rifinah Rifinah Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Creat	Tabs mg Tabs m mg intinue Regin Construction	Aletra (0.125ml/kg): ABC (8mg/kg): DDI (100mg/m2) Nelfinavir: Other: en Change Reg Weight Change apsone mg/day ntinue INH R (Specify) Di to Continuation Cr cify) Rifafour BCG Measles Polio Formula Solid food (Intolerance Othe Freg & Duration	Syrup Syrup Syrup Powder e-dose e-dose a Acting to Dose: ontinue Regin ht Change tabs/day Dose#: Dose#: Dose#: Dose#: Congali, potatoe r(Specify): Viral Load Other (Specify): Viral Load Other (Specify): Viral Load	mgng	mlTal mlTa mlTa mlTa mlTa mlTa mlTa mlTa mlTa mg/day na mg/day	osm
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): □ Tabs □ AZT: (180mg/m2): □ Syrup □ NVP: □ Syrup mg □ EFV: □ Syrup mg □ 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None New Drugs: Septrin tab: 24c. TB Prophylaxis: □ None Reason for stop/change/re-dose: None Reason for stop/change/re-dose: None Reason for stop/change/re-dose: None 24d. TB Treatment: □ None □ Streptomycin	mgm mm mm mm m siday or siday or siday 	ml Tabs 20 30 mg 20 30 mg g ml 1 Tabs mg art Co ity (Specify) ml/day Start INH leted ht Change rt Induction bleted 1 Rifinah_ Rifiampic Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Creat gram A SGP	Tabs mg Tabs m ng ntinue Regin Coin Coin Coin Coin Coin Coin Change Toxicity (Spectrum tabs/dt cin mg Change Toxicity (Spectrum tabs/dt cin mg Change Toxicity (Spectrum tabs/dt cin mg Coin Coin Change Toxicity (Spectrum tabs/dt cin mg Change Toxicity (Spectrum tabs/dt cin mg Coin mg Change Toxicity (Spectrum tabs/dt cin mg Coin mg coin mg Coin mg coin mg coin mg coin mg coin coin mg coin mg coin coin coin mg coin _	Aletra (0.125ml/kg): ABC (8mg/kg): g DDI (100mg/m2) Netfinavir: 0 Other: nen Change Reg weight Change apsone mg/day ntinue INH R (Specify) 0 to Continuation CC cify) Rifafour BCG Neasles Polio BCG Neasles Polio Solid food (Intolerance Othe Freq & Duration CCD4 Panel CXR	Syrup Syrup Syrup Powder e-dose e-dose a Other to Dose#: 0 1 Dose#: 0 1 Dose#: 0 1 Dose#: 0 1 Cougali, potatoe r(Specify): Viral Load Other (Specify): Viral Load Other (Specify): OVC OVC	mgng	mlTal mlTal mlTa mlTa Ta Ntal mg/day 	os m os m bs m bs m bs m mg/day mg Dose
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): : □ Tabs □ AZT: (180mg/m2): □ Syrup mg □ KVP: □ Syrup mg □ EFV: □ Syrup mg □ 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: New Drugs: □ Septrin 24c. TB Prophylaxis: □ None Reason for stop/change/re-dose: New Drugs: □ Streptomycin 24c. TB Treatment: □ None Reason for stop/change/re-dose: New Drugs: □ Rifatertab: □ Streptomycin 24e. Immunizations Ordered T □ Pentavalent □ 1 □ Additional Comments: □ Other liqui I this is a change, reason for cha 24g. Other Drugs Started or R Drug □ □ 1. □ □ 25. Tests Ordered: □ FB treatment/□ □ None □ TB treatment/□	mgm mm mm mm m 	ml Tabs 20 30 mg 20 30 mg g ml 1 Tabs mg ml/day Start INH leted Start INH leted 1 Rifinah_ Rifiampic None Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Creat gram A Heath	Tabs mg Tabs m ng ntinue Regin Coin Coin Change Toxicity (Spectration (Spectration) Change Toxicity (Spectration) Constant C	Aletra (0.125ml/kg): ABC (8mg/kg): g DDI (100mg/m2) Netfinavir: 0 Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify) 0 to Continuation CC cify) Rifafour 8 Rifafour 9 Rifafour 9 Rifafour 9 BCG 1 Measles 2 Polio 3 Solid food (1 Intolerance Othe Freq & Duration 2 CD4 Panel 2 CXR	Syrup Syrup Syrup Syrup Powder e-dose a Actinug Dose: ontinue Regin th Change Dose#: 1 Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose	mg	mlTal mlTal mlTa mlTa Ta Ntal mg/day 	ossm bsm bsm bsm mg/day mg
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): □ Tabs □ 44T (1mg/kg): □ Tabs □ AZT: (180mg/m2): □ Syrup □ NVP: □ Syrup □ EFV: □ Syrup □ 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None New Drugs: □ Stop/change/re-dose: New Drugs: □ Stop/change/re-dose: 24c. TB Treatment: □ None Reason for stop/change/re-dose: □ Streptomycin 24c. TB Treatment: □ None □ Streptomycin □ Streptomycin 24c. TB Treatment: □ None □ Streptomycin □ Streptomycin 24c. Immunizations Ordered T □ H □ Pentavalent □ I □ Vaocine □ I □ Streptomycin □ Other Drugs Started or R Drug □ □ 1. □ □ 25. Tests Ordered: □ FB treatment/□ □ None □ TB trea	mgm mm mm mm m 	ml Tabs 20 30 mg 20 30 mg g ml 0 ITabs mg ml/day Start INH leted Start INH leted 1 Rifinah_ Rifiampic None Dose#: 0 Dose#: 0 Dose	Tabs mg Tabs mg ntinue Regin Co 	Aletra (0.125ml/kg): ABC (8mg/kg): DDI (100mg/m2) Netfinavir: Other: weight Change Reg Weight Change apsonemg/day ntinue INHR (Specify)D to ContinuationC cify)O to ContinuationC ContinuationC con	Syrup Syrup Syrup Syrup Powder imen Re Other actinue Regin th Change th Change Dose#: 1 Dose#: 1 Dose#: 1 Dose#: 1 Con Con Con Con Con Con Con Con	mg	mlTal mlTal mlTa mlTa Ta Ntal mg/day 	ossm bsm bsm bsm mg/day mg
□ 3TC (4mg/kg): □ Syrup □ 44T (1mg/kg): □ Tabs □ A4T: (180mg/m2): □ Syrup □ NVP: □ Syrup mg □ EFV: □ Syrup mg □ 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: None Reason for stop/change/re-dose: ■ 24d. TB Treatment: □ None Reason for stop/change/re-dose: ■ 24d. TB Treatment: □ None Reason for stop/change/re-dose: ■ □ Streptomycin 24e. 24e. Immunizations Ordered T □ □ Pentavalent □ □ Strest Orderedt □ □	mgm mm mm mm sta: sta: sta: sta: mg 	ml Tabs 20 30 mg 20 30 mg g_ml 0 ITabsn Tabsn Tabsn Ml(day Start INH leted t Induction leted 1 Rifinah_ Rifianpic Rifianpic Rifianpic None Dose#: 0 Dose#: 0 Dose#	Tabs mg Tabs mg ntinue Regin Co Co Toxicity (Spectric tabs/dt cin mg 1 2 3 1 3 1 2 3 1 2 3 1 3	Aletra (0.125ml/kg): ABC (8mg/kg): g DDI (100mg/m2) Nelfinavir: Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify)D to Continuation CC cify) Weight NHmg BCG Measles Polio BCG Measles Polio Freq & Duration Freq & Duration CCD4 Panel CXR CO/Physiciar Nurse:	Syrup Syrup Syrup Syrup Powder e-dose ontinue Regin th Change th Changeth Change _	mg	ml Tal ml Tal ml Ta ml Ta ml Ta ml Ta ml Ta ml Tal ml Talml Talml Talml Talml Talml Talml Talml Talml Talml Talml	os m os m bs m bs m bs m mg/day mg/day mg

Appendix B: AMPATH Rural Health Centre Pediatric Clinical Encounter Form

	3 names	– given,	middle	e, family):		2. AMR	S ID:		3. Old MN	IRS ID:	4. H	ICT ID:	
5. Age:	Yrs		Mo		Days _		6. Sex:] F	7. Marital	Status: 🗆	S DM		V DS
8. Next of	Kin:				9. P	hone #:				10. Occup	ation:			
11. Clinic	Child< 5	Child 5+	Adult	FamPlan	STI	Chest/TB	Dental	ENT	Eye	PhysT Occ T Plaste			Psych	Othe
New														
Return														-
2. Main I	Problem	(today):								Dur	ation of ill	ness (days	i)	_
None (preventive	e care, fo	llow-up), etc.)										
Prior Car	e for this	Problem	n: 🗆 N	lone	□Self-r	medicate	d DT	raditiona	l healer	Priva	te Pharma	icy 🗆	CHW	
3. Vital 5 BP:	Signs:	Pulse	e		Weight	E 1	ka He	eiaht:	cm	Temp:	°(Head	circ	cm
feuel Aer	uite D		1.	,										
				Vac.	No. E	111/4		15 Tee	ted for H	IIV todav?:	Vec		1N/A	
4. Couns amily Pl 6. Contra	seled on H anning C aception (IIV today Iinic Dat check all	a that ap	ply): C c	condoms	s 🗆 IU	D 🗆 si	FP #:	(IfY n □ na	tural FP	Test result	in test ser	ction)	🗆 pi
4. Couns amily PI 6. Contra ☐ Other:_ Paediatric	anning C aception (c Clinic D	IIV today Iinic Dat check all Data	r: L	ply): a c	ondom	s 🗆 IU	D 🗆 st	FP #:	(ifY n □ na	tural FP	☐ Test result	in test ser gm □ De	poProvera	🗆 pi
4. Couns amily Pl 6. Contra Other: 7. Under	anning C aception (c Clinic D rweight?	IIV today IInic Dat check all Data	that ap	ply): a c Notes:	condoms	s 🗆 IU	D 🗆 st	FP #: terilization	(If Y n 🗆 na with ITN	tural FP [diaphrag	in test ser	poProvera	□ p
A. Couns amily Pl 6. Contra Other: Paediatric 7. Under 9. Dange f Yes:	anning C aception (c Clinic D rweight? ar Signs t Unable to Other urg	IIV today Iinic Dat check all Data Ves this visit o drink or gent sign	r: U a that ap s ? V r breast deman	ply): C o Notes: No No Yes C feed C ding imm	ondom:	s D IU	D St	FP #: , terilization 8. Issued 1 Has had ough or o	(If Y	tural FP [I tes Test result I diaphra I diaphra I Yes ethargic I Diarrho	in test ser gm De No Uncons pea Fe	poProvera	D pi
4. Couns amily PI 6. Contra Other: Paediatriv 7. Under 9. Dange f Yes:	aception (aception (c Clinic D rweight? er Signs t I Unable to Other urg al Comme	IV today Inic Dat Check all Data Yes this visit o drink or gent sign Ear Prot onts:	r: D that ap s D r breast deman	ply): c Notes: No Yes c feed c ding imm Other:	ondom:	s D IU	D Si	FP #: . terilization 8. Issued 1 Has had ough or o	(If Y n na with ITN d convuls difficulty	i today?	Test result diaphray Ves ethargic Diarrho	in test see	poProvera scious aver	□ p
4. Couns amily PI 6. Contra Other: 9. Dange f Yes:	anning C aception (c Clinic D rweight? ar Signs t Unable to Other ur; al Comme	IIV today IInic Dat check all Data Data Data Data Chis visit o drink or gent sign Ear Prot onts:	r: L 1 that ap s C 1 r breast deman blem C	ply): c Notes: No Yes c feed ding imm Other:	ondom:	s 🗆 IU	D SI	FP #: terilization 8. Issued 1 Has had lough or o	(If Y n na with ITN d convuls	tural FP [I diaphra	in test see gm De	poProvera scious aver	_ p
4. Couns amily Pl amily Pl 6. Contra Other: Dadditrin additiona Co. Immu	c Clinic D aception (c Clinic D rweight? er Signs t Unable tr Other urg al Comme	IIV today IInic Dat check all Data Yes this visit o drink or gent sign Ear Prot onts: Given T teoR. Hib	r: L 1 that ap s C 1 r breast deman blem C	ply): C Notes: No Yes C feed C ding imm Other:	No L No l Vomiti nediate	s IU	D st	FP #: terilization 8. Issued 1 Has had lough or o	(If Y n na with ITN d convuls difficulty	tural FP [Test result Test result diaphra Ves ethargic Diarrho	in test see gm De	poProvera scious aver	□ p
Couns amily Pl amily Pl Contra Other:_ Other:_ Other:_ Other:_ Additiona Additiona Contravale Pontavale Polio	c Clinic D c Clinic D rweight? er Signs t Unable to Other urg al Comme nizations int (DTP-F	IV today Iinic Dat check all Pata Yes this visit o drink or gent sign Ear Prot mts: Given T lepB-Hib	r: L ' a that ap s L r breast deman olem [oday:)	ply): c Notes: No Yes c feed c ding imm Other:	3 No J Vomiti nediate	s IU	D st	FP #: terilization 8. Issued 1 Has had ough or o	(If Y n na with ITN d convuls difficulty BCG Meas	I today?	Test result Test result diaphra diaphra thargic Diarrho	in test see	poProvera accious aver	Reva
4. Couns amily Pl 6. Contra Other: Other: Paediatrik Paediatrik Paediatrik Additiona Other Contra Co	C Clinic D aception (c Clinic D rweight? er Signs t I Unable to Other urg al Comme nizations int (DTP-H wer	IV today Inic Dat Check all Pata Yes this visit o drink or gent sign Ear Prot onts: Given T tepB-Hib	r: L Y that ap s Y r breast deman blem []	ply): C Notes: No Yes C feed C ding imn Other:	3 No J Vomiti nediate	s IU	D st	FP #: terilization 8. Issued 1 Has had cough or o	(If Y n na with ITN d convuls difficulty BCG Meas Hepa	I today? itural FP [itural FP [itural FP] itural FP [itural FP] itural FP [itural FP] itural FP [itural FP] itural FP] itural FP [itural FP] itural FP	Test result Test result diaphrag thargic Diarrho	in test see gm De	opoProvera	Reva 2 2
4. Couns amily Pl 6. Contra Other: Other: Additiona Contra	aception (aception (IV today Inic Dat Check all Check all Pata Yes this visit o drink or gent sign Ear Prot onts: Given T HepB-Hib	r: L 1 that ap s L 1 r breast deman blem C 'oday:)	ply): C Notes: No Yes C feed C ding imn Other: 0	I No I Vomiti nediate	s IU	D St	FP #: terilization 8. Issued 1 Has had yough or o	(If Y n na with ITN d convuls difficulty BCG Meas Hepa	es, record tural FP [i today? sions] L breathing les titis A	Test result Test result diaphrag Test result Diarho	in test ser gm De	ction) poProvera ccious ever	Reva 2 2
4. Couns amily PI 6. Contra Other: Other: Additiona Contra	c Clinic D c Clinic D rweight? ar Signs t Unable to Other urg al Comme nizations int (DTP-H ver	IIV today IInic Dat Check all Pata Yes this visit o drink or gent sign Ear Prot mts: Given T lepB-Hib plete?	r: L 1 that ap s L 1 r breast deman blem C r oday:) Ye:	ply): c Notes: No Yes c ding imn Other: 0	I No Vomiti nediate	s IU	D St	FP #: terilization B. Issued I Has had cough or o	(If Y n □ na with ITN d convuls difficulty BCG Meas Hepa	es, record tural FP [i today? sions] L breathing les titis A r Present?	Test result	in test ser in test ser in De in test ser in De in De in De	ction) poProvera cous aver	Reva 2 2
4. Couns amily PI formally PI formaly PI formally PI formally PI formally PI formally PI formally PI f	c Clinic D aception (aception (c Clinic D rweight? ar Signs t Unable t Other urg al Comme nizations at Comme nizations mit (DTP-H ver tions Com	IIV today IInic Dat Inic Dat Check all IIIIC Dat Check all IIIIC Dat IIIIC Dat IIIIC Dat IIIIC Dat IIIIC Dat IIIIIC Dat IIIIIC Dat IIIIIC Dat IIIIIC Dat IIIIIIC Dat IIIIIIC Dat IIIIIIIC Dat IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	r: L Yes	ply): c Notes: Notes: Mo Yes c feed c ding imm Other: 0 0 0 0 0 0 0 12-17 mo	I No I Vomiti nediate	s IU ng every attention 23 2 o	D St	FP #: terilization 8. Issued 1 Has had lough or of 3 3 3 3 3 3 3 3 3 3 3 3 3	(If Y n □ na with ITN d convuls difficulty BCG Meas Hepa SCG Sca m	I today? I today? I today? Sions L L breathing I today? I to	Test result Test result diaphrag diaphrag Test Test result Diarrho Test Test	in test see gm De No Uncons Dea Fe No 48-53 mo	Ction) poProvera ccious aver 0 1 1 54-59 mo	Reva 2 2 60 me
4. Couns amily Pl amily Pl 6. Contra Other: Paediatric	c Clinic D aception (aception (c Clinic D rweight? er Signs t Unable tr Other urg al Comme nizations int (DTP-H ver tions Com min A: lary Serv	IIV today IIIIIC Dat Check all Check	r: L T	ply): c Notes: No Yes c feed c ding imm Other: 0 0 s N 12-17 mo	I No I Vomiti nediate	s IU ng every attention 23 2 o	D St	FP #: terilization 8. Issued 0 Has had ough or of 3 3 3 	(if Y n □ na with ITN d convuls difficulty BCG Meas Hepa BCG Sca BCG Sca m	I today? I today? I today? Sions L breathing les titis A r Present? 41 4: o 1	Test result Test result diaphra diaphra thargic Diarrho Diarrho Yes Yes Yes Yes Yes	in test see in test see m De Uncons Dea Fee No 48-53 mo	ction) poProvera ccious aver 0 1 1 54-59 mo	Reva 2 2 60 m
4. Couns amily PI 6. Contra Other: Other: Paediatriv 7. Under 9. Dange f Yes: Count Additiona 20. Immu Pentavale Polio fellow Fe Other: mmunizal 21. Vita 22. Ancil Medica	aception (aception (aception (c Clinic D rweight? ar Signs t Unable to Other urq D al Comme al Comme nizations int (DTP-I- tions Com min A: lary Serv al Exam	IV today IInic Dat Inic Dat Check all I Yes this visit o drink or	r: L Yes cal Rep	No Notes: No Yes C feed C ding imm Other: 0 0 s N No Yes C feed C ding imm Other: 0 0	I No I Vomiti nediate	s IU s IU ng every attention 23 2 o r of Paris	D SI 118 thing C 2 2 4-29 mo 5 Dr	FP #: terilization 8. Issued 1 Has had cough or of 3 3 3 3 	(If Y n na with ITN d convuls difficulty BCG Meas Hepa SCG Sca m	I today? I today? I today? Sions D L breathing I today? I to	Test result Test result diaphrag diaphrag thargic Diarrho Diarrho Test Yes thargic Yes Yes Yes Yes	in test see	opoProvera	Reva 2 2 60 m
4. Couns amily Pl 6. Contra Other: Other: Paediatric Other: Paediatric Paedia	c Clinic D aception (aception (IIV today IInic Dat Inic Dat Check all Pata Pata Prot Order Sign Ear Prot Order T TepB-Hib Order C ICes INedi	r: L Yes	ply): c Notes: No Yes c feed c ding imm Other: 0 0 s N 12-17 mo	I No I Vomiti nediate	s IU ng every attention 23 2 o r of Paris	D St 18 thing 1 thing 1 thing 1 2 2 4-29 mo thing 1 C	FP #: terilization 8. Issued 1 Has had lough or of 3 3 3 3 	(If Y n na with ITN d convuls difficulty BCG Sca Hepa BCG Sca BCG Sca G Sca	itural FP [itural	Test result Test result diaphrag diaphrag Diarrho Diarrho Yes Yes 2-47 mo	in test see gm De No Uncons Dea Fe	ction) poProvera colous aver 0 1 1 54-59 mo	Reva 2 2 60 m

24. Test Results:			Blood suga	r.			Below	norm		nal		ormal		
VDRL:			biood suga	·			Delow	nomik				ornar	-	
Malaria smear:			Hgb:				HVS:		D					
Pregnancy Test: _			Blood Grou	ip:					cells	Yeas		ls ⊡Gi	VCs	ŝ
Widal Test:			Other:				Urina	alysis	us ⊔ :⊡NAD	GPR	5			
Brucella Test: :	Aborteus		Mellitiues:					s cells	: 0+]++ []	+++		
Sputum for AFB:	New Test	1 st	2 nd	. 3	rd	-								
	Follow-up test;							gairi	coont. LI					
HIV Rapid Test:	BIOLINE:		UNIGO	XLD:			Stool	Exan	1:			_		
Other ():						Other	_					_	
X- Ray 1:													_	
Ultrasound:												-	_	
25. Diagnoses Th	is Visit:								New		Continue	Resolve	bd	
1.								_						
2.								_					1	
3.								_		_				
4.					_	-								_
26. Drugs Given 1	This Visit					Dose		Freque	incy	Dur	ation	Picked	up	
1.													-	
2.										<u> </u>			-	
3.													_	
4.													-	
5.							_						-	
6.													_	
7.				_	_		-							
27. Financial Office	1	Kaba						Signat	ure:	K-L		-		
Item:		Ksh:		Exampt	Warver	Item:				Ksh	:	Exem	PE	Mark
					-								+	
													+	
28. Referrals														
Referrals: None		Kapsabet D	istrict Hospit	al 🗆	Nandi	Hills Dist	rict Hos	pital	CO/Phys	ician				
C Admit	to Mosoriot Inco	tient Unit	Other						Dentitye	all.				
Reason for Deferre	ale motorior inpe	and one							Provider	#:				-
Followup Needed?	: OYes ON	lo Type	of Followup:						Nurse:					-
Return to Clinic: D	ays:Wee	(S:	Months:	Da	ate:	1	<u></u>	_	Provider	#:				_
Registration Fields	: Date of Birth:			_ Fathe	er's Ful	I Name:	:							
Mother's Full Nam	8::				Guard	ian's Ful	I Name:	:						
0.0	ing nationt:				Nex	t of Kin:								
Other person bring						the second se				_			-	-